EP4271208A1 - Fermented extract of longoza seeds - Google Patents
Fermented extract of longoza seedsInfo
- Publication number
- EP4271208A1 EP4271208A1 EP21854927.7A EP21854927A EP4271208A1 EP 4271208 A1 EP4271208 A1 EP 4271208A1 EP 21854927 A EP21854927 A EP 21854927A EP 4271208 A1 EP4271208 A1 EP 4271208A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- skin
- longoza
- extract
- seeds
- fermented extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 194
- 239000000203 mixture Substances 0.000 claims abstract description 90
- 210000003491 skin Anatomy 0.000 claims abstract description 86
- 239000002537 cosmetic Substances 0.000 claims abstract description 43
- 230000004075 alteration Effects 0.000 claims abstract description 28
- 210000004927 skin cell Anatomy 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 206010040844 Skin exfoliation Diseases 0.000 claims abstract description 10
- 230000035618 desquamation Effects 0.000 claims abstract description 10
- 230000037303 wrinkles Effects 0.000 claims abstract description 9
- 238000000855 fermentation Methods 0.000 claims description 58
- 230000004151 fermentation Effects 0.000 claims description 58
- 244000005700 microbiome Species 0.000 claims description 43
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 25
- 239000003755 preservative agent Substances 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 20
- 244000269722 Thea sinensis Species 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 19
- 150000001720 carbohydrates Chemical class 0.000 claims description 18
- 235000011187 glycerol Nutrition 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 17
- 102000011782 Keratins Human genes 0.000 claims description 16
- 108010076876 Keratins Proteins 0.000 claims description 16
- 230000002335 preservative effect Effects 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 230000004888 barrier function Effects 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 238000011534 incubation Methods 0.000 claims description 13
- 244000034356 Aframomum angustifolium Species 0.000 claims description 10
- 235000010166 Aframomum angustifolium Nutrition 0.000 claims description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 239000006286 aqueous extract Substances 0.000 claims description 9
- 230000009759 skin aging Effects 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 235000018811 Aframomum Nutrition 0.000 claims description 8
- 241001127758 Aframomum Species 0.000 claims description 8
- 229930091371 Fructose Natural products 0.000 claims description 8
- 239000005715 Fructose Substances 0.000 claims description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 7
- 241000186660 Lactobacillus Species 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 229940039696 lactobacillus Drugs 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 5
- 241000589220 Acetobacter Species 0.000 claims description 5
- 241000589236 Gluconobacter Species 0.000 claims description 5
- 241001474750 Komagataeibacter Species 0.000 claims description 5
- 241000192001 Pediococcus Species 0.000 claims description 5
- 241000235070 Saccharomyces Species 0.000 claims description 5
- 241000235006 Torulaspora Species 0.000 claims description 5
- 230000003712 anti-aging effect Effects 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 235000013379 molasses Nutrition 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 claims description 4
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 claims description 4
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 3
- 239000003974 emollient agent Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 230000003020 moisturizing effect Effects 0.000 claims description 3
- 239000007764 o/w emulsion Substances 0.000 claims description 3
- 239000004302 potassium sorbate Substances 0.000 claims description 3
- 235000010241 potassium sorbate Nutrition 0.000 claims description 3
- 229940069338 potassium sorbate Drugs 0.000 claims description 3
- 235000013772 propylene glycol Nutrition 0.000 claims description 3
- UVVPZMPJAYXZDN-UHFFFAOYSA-M sodium;benzoic acid;benzoate Chemical compound [Na+].OC(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 UVVPZMPJAYXZDN-UHFFFAOYSA-M 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000002304 perfume Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 8
- 230000032683 aging Effects 0.000 abstract description 7
- 230000008591 skin barrier function Effects 0.000 abstract description 6
- 239000002609 medium Substances 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 210000002510 keratinocyte Anatomy 0.000 description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 239000002994 raw material Substances 0.000 description 13
- 235000013616 tea Nutrition 0.000 description 13
- 239000007864 aqueous solution Substances 0.000 description 12
- 210000004207 dermis Anatomy 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000004630 atomic force microscopy Methods 0.000 description 10
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 8
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 108010045579 Desmoglein 1 Proteins 0.000 description 7
- 102100034579 Desmoglein-1 Human genes 0.000 description 7
- 102100023795 Elafin Human genes 0.000 description 7
- 108010015972 Elafin Proteins 0.000 description 7
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 230000035882 stress Effects 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 102100031784 Loricrin Human genes 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 239000000976 ink Substances 0.000 description 6
- 108010079309 loricrin Proteins 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 235000006468 Thea sinensis Nutrition 0.000 description 5
- 108060008539 Transglutaminase Proteins 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 210000002514 epidermal stem cell Anatomy 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000003601 transglutaminase Human genes 0.000 description 5
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 102100028314 Filaggrin Human genes 0.000 description 4
- 101710088660 Filaggrin Proteins 0.000 description 4
- 102100034868 Kallikrein-5 Human genes 0.000 description 4
- 101710176223 Kallikrein-5 Proteins 0.000 description 4
- 235000020279 black tea Nutrition 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000012109 Alexa Fluor 568 Substances 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 240000006024 Lactobacillus plantarum Species 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 229940095714 cider vinegar Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 235000021419 vinegar Nutrition 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000000426 Integrin alpha6 Human genes 0.000 description 2
- 108010041100 Integrin alpha6 Proteins 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 235000018370 Saccharomyces delbrueckii Nutrition 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 244000288561 Torulaspora delbrueckii Species 0.000 description 2
- 235000014681 Torulaspora delbrueckii Nutrition 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 238000000418 atomic force spectrum Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 238000007417 hierarchical cluster analysis Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- -1 loricrine Proteins 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229960002181 saccharomyces boulardii Drugs 0.000 description 2
- 239000004248 saffron Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- 238000012584 2D NMR experiment Methods 0.000 description 1
- VIBDVOOELVZGDU-UHFFFAOYSA-N 4-(1h-indol-2-yl)benzene-1,3-dicarboximidamide Chemical compound NC(=N)C1=CC(C(=N)N)=CC=C1C1=CC2=CC=CC=C2N1 VIBDVOOELVZGDU-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000589218 Acetobacteraceae Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000032681 Gluconacetobacter Species 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 241001468155 Lactobacillaceae Species 0.000 description 1
- 241001112724 Lactobacillales Species 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 241001185316 Rhodospirillales Species 0.000 description 1
- 241000235344 Saccharomycetaceae Species 0.000 description 1
- 241000235343 Saccharomycetales Species 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000009329 organic farming Methods 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000008491 skin homeostasis Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
- A23L25/40—Fermented products; Products treated with microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Definitions
- the present invention relates to the cosmetic field and in particular to a fermented extract of Longoza seeds as well as the fermentation process for obtaining it, a cosmetic composition containing said fermented extract of Longoza seeds, and its use in a cosmetic care process. and/or for making up keratin materials.
- aging is induced by endogenous (eg: stress, hormones, etc.) and exogenous (eg: temperature, climate, UV radiation, atmospheric pollution, cigarette smoke, etc.) factors leading to a slowdown and/or an alteration of various cellular functions.
- endogenous eg: stress, hormones, etc.
- exogenous eg: temperature, climate, UV radiation, atmospheric pollution, cigarette smoke, etc.
- aging is manifested by various clinical signs, in particular by a reduction in epidermal renewal, an alteration of the cutaneous barrier, a loss of firmness and elasticity of the skin, a reduction in the thickness of the skin, the appearance of fine lines or wrinkles, the appearance of a less even complexion, and/or drier skin.
- the Applicant demonstrated the 'anti-aging' effects of a fermented extract of Longoza seeds in vitro on a skin model.
- the fermented extract of Longoza seeds advantageously makes it possible to improve the structure of the skin, which notably becomes thicker, with a very clear basal organization and structured dermo-epidermal junctions.
- the fermented extract of Longoza seeds advantageously makes it possible to increase the expression of various proteins involved in the mechanical solidity of the skin as well as its renewal and its elasticity, such as elafin, desmoglein 1 , loricrine, transglutaminase and ZO-1 , ultimately promoting cellular integrity and skin cell homeostasis.
- the fermented extract of Longoza seeds is in particular used according to the invention as a cosmetic active ingredient intended to promote and/or stimulate epidermal renewal, desquamation of the skin, the vitality of the skin cells and/or the cohesion of the skin cells, and /or prevent and/or reduce the signs of skin aging, in particular loss of firmness, loss of elasticity, loss of density, appearance of wrinkles and/or fine lines, dryness of the skin, alteration of the barrier function of the skin, the alteration of the suppleness of the skin and/or the alteration of the homogeneity or the radiance of the complexion.
- the first object of the invention therefore relates to a fermented extract of Longoza seeds comprising a quinic acid content of between 0.05 and 2% and an acetic acid content of between 5 and 15%, by weight relative to the weight of dry extract of the fermented extract.
- Another object of the invention relates to a process for the fermentation of Longoza seeds comprising the following steps: a) the incubation of a consortium of microorganisms in a solution comprising a carbohydrate at a temperature between 17 and 38° C for 1 to 10 days in order to obtain a culture of microorganisms, said consortium comprising at least one lactic acid bacterium belonging to the genus Lactobacillus or Pediococcus, at least one yeast belonging to the genus Saccharomyces, Schyzosaccharomyces or Torulaspora, and at least one bacterium acetic acid belonging to the genus Acetobacter, Gluconobacter or Komagataeibacter; b) the grinding of Longoza seeds in order to obtain a powder composed of particles having an average size of between 100 ⁇ m and 1 mm; c) adding said powder to a fermentation medium comprising the culture of microorganisms in order to obtain a fermentation mixture, said fermentation medium comprising a carb
- Another object of the invention relates to a fermented extract of Longoza seeds obtained by the method as described according to the invention.
- the invention also relates to a cosmetic composition
- a cosmetic composition comprising, in a physiologically acceptable medium, a fermented extract of Longoza seeds.
- Another object of the invention relates to a cosmetic process for caring for and/or making up keratin materials, in particular the skin and/or the lips, comprising the application to said keratin materials of at least one layer of the composition cosmetic as described according to the invention.
- the invention finally relates to the cosmetic use of a fermented extract of Longoza seeds according to the invention as an active ingredient for promoting and/or stimulating epidermal renewal, desquamation of the skin, the vitality of skin cells, and/or the cohesion of skin cells, and/or preventing and/or reducing the signs of skin aging, in particular loss of firmness, loss of elasticity, loss of density, appearance of wrinkles and/or fine lines, dryness of the skin, the alteration of the barrier function of the skin, the alteration of the suppleness of the skin and/or the alteration of the homogeneity or the radiance of the complexion.
- FIG. 1 Effect of fermented Longoza seed extract on loricrin expression
- FIG. 7 Effect of Fermented Longoza Seed Extract on ZO-1 Expression
- FIG. 8 Histological analysis of the effect of Longoza seed fermented extract on a skin model
- the Longoza is a fruit of ['Aframomum an ustifolium, a plant of the ginger family. This plant is characterized by an exceptional regeneration by the root since it grows even after cutting and burning. It is one of the pioneer plants that grow back on land burned during forest fires in Madagascar.
- the fermented extract of Aframomum an ustifolium or Longoza is obtained from the seeds of the Aframomum an ustifolium or Longoza plant.
- seeds of Longoza here for simplification, this obviously means indifferently seeds of Aframomum an ustifolium or Longoza.
- Longoza seeds are used in a fermentation process in order to generate a fermented extract of Longoza seeds, object of the present invention.
- the expression "fermented extract” designates the product resulting from the fermentation process by fermentation, with or without filtration, therefore both with and without the microbial biomass of the fermentation medium, as well as any product having undergone additional steps, such as a formulation step (eg by adding a preservative).
- the fermented extract of Longoza seeds according to the invention is in the form of an aqueous solution of fermented extract comprising the fermented dry extract, water and a preservative.
- the fermented extract in the form of an aqueous solution is also called 'raw material' in the description, as opposed to 'dry matter' or fermented dry extract.
- the aqueous solution of fermented extract comprises the fermented extract in an active content (dry matter) ranging from 0.5 to 3% by weight, in particular 1 to 2% by weight and in particular 1.2 to 1.7% by weight of active material relative to the total weight of raw material (aqueous solution of fermented extract), water and a preservative, preferably glycerin.
- the water content will generally range from 20 to 40% by weight, in particular from 25 to 30% in particular from 27 to 29% by weight relative to the total weight of raw material (aqueous solution of fermented extract) and the preservative content (for example: glycerin) will generally range from 60 to 80% by weight, in particular from 65 to 75% by weight, in particular 70% by weight relative to the total weight of raw material (aqueous solution of fermented extract).
- the preservative content for example: glycerin
- the invention also relates to a fermented extract of Longoza seeds in the form of a solution comprising 1 to 2% by weight of active ingredient of fermented extract of Longoza seeds, 65 to 75% by weight of glycerin and 25 to 30% by weight of water.
- the aqueous solution of fermented extract comprises 1.2 to 1.65% in active matter (dry matter) of fermented extract, 70% of glycerine and 28.35 to 28.8% of water relative to the total weight of raw material (aqueous solution of fermented extract).
- the aqueous solution of fermented extract otherwise called 'raw material' in the characterization which is illustrated below, comprises 1.2 to 1.35% in active matter (dry matter) of fermented extract, 70% glycerin and 28.65 to 28.8% water relative to the total weight of raw material (aqueous solution of fermented extract).
- the aqueous solution of fermented extract otherwise called 'raw material' in the characterization which is illustrated below, comprises 1.35 to 1.65% in active matter (dry matter) of fermented extract , 70% glycerin and 28.35 to 28.65% water relative to the total weight of raw material (aqueous solution of fermented extract).
- the fermented extract of Longoza seeds comprises a quinic acid content greater than 0.005%, preferably between 0.005 and 10%, and an acetic acid content greater than 0.5%, preferably between 0.5 and 25%, by weight relative to the weight of dry extract (dry matter) of the fermented extract.
- the fermented extract of Longoza seeds comprises a quinic acid content of between 0.01 and 5%, more preferably between 0.05 and 2% by weight relative to the dry extract weight of the extract fermented.
- the extract fermented Longoza seeds comprises an acetic acid content of between 1 and 20%, more preferably between 5 and 15% by weight by weight relative to the dry extract weight of the fermented extract.
- Longoza seed fermented extract may include other organic acids, such as citric acid, gluconic acid, lactic acid, malic acid, and succinic acid. Also, the fermented extract of Longoza seeds may include:
- citric acid content of between 0.01 and 5%, preferably between 0.05 and 2%, more preferably between 0.1 and 1%, even more preferably between 0.2 and 0.4% by weight relative the dry extract weight of the fermented extract,
- gluconic acid content greater than 0.5%, preferably between 0.5 and 25%, more preferably between 1 and 20%, even more preferably between 1 and 15% by weight relative to the weight of dry extract fermented extract,
- a malic acid content of between 0.001 and 5%, preferably between 0.005 and 1%, more preferably between 0.008 and 0.5% by weight relative to the dry extract weight of the fermented extract, and/or
- succinic acid content of between 0.001 and 5%, preferably between 0.005 and 1%, more preferably between 0.01 and 0.05% by weight relative to the dry extract weight of the fermented extract.
- the fermented Longoza seed extract does not include glucuronic acid or propionic acid.
- the fermented Longoza seed extract may also include one or more preservatives.
- preservative is meant a compound whose purpose is to preserve the composition of the extract or the cosmetic containing it from any physico-chemical and/or microbial alteration.
- at least one preservative is chosen from butylene glycol, glycerin, propylene glycol, sodium benzoate benzoate and potassium sorbate, more preferentially glycerin.
- the fermented extract may in particular comprise one or more preservative(s) at a final concentration of between 60 and 80%, preferably between 65 and 75%, more preferably 70% by weight relative by total weight, preferably at least one of the preservatives described above chosen from butylene glycol, glycerin and propylene glycol.
- This fermented extract of Longoza seeds is obtained by a fermentation process comprising steps of: a) incubation of a consortium of microorganisms in a solution comprising a carbohydrate and optionally in addition an aqueous extract of tea leaves at a temperature between 17 and 38°C in order to obtain a culture of microorganisms; b) grinding seeds of Aframomum angustifolium or Longoza to obtain a fine powder; c) adding said powder to a fermentation medium comprising the culture of microorganisms and a carbohydrate in order to obtain a fermentation mixture; c) incubation of the fermentation mixture at a temperature between 12 and 42° C. for 2 to 20 days; d) filtration of the fermentation mixture, in order to obtain a fermented extract of Longoza seeds; and, optionally, e) adding at least one preservative.
- Fermentation process is meant a process making it possible to obtain a fermented extract of Longoza seeds by culturing a consortium of microorganisms as defined here in a medium containing a carbohydrate and allowing their growth.
- the fermentation can take place under conditions of discontinuous culture (in “batch”), of continuous culture, or in continuous-discontinuous (in “Fed batch”). Fermentation can be carried out aerobic, micro-aerobic and/or anaerobic.
- consortium of microorganisms is meant an assembly of at least three species of microorganisms that can coexist in a stable and reproducible manner.
- the microorganisms make it possible to combine complementary activities.
- the use or assimilation of a carbon source by a first species makes it possible to produce metabolites which can then be metabolized by a second species.
- the consortium of microorganisms according to the present invention comprises: i) at least one microorganism belonging to the group of lactic acid bacteria, ii) at least one microorganism belonging to the group of yeasts, and iii) at least one microorganism belonging to the group of acetic acid bacteria.
- At least one microorganism belonging to the group of lactic acid bacteria is a microorganism of the order Lactobacillales of the Lactobacillaceae family, in particular those belonging to the genera Lactobacillus and Pediococcus, such as Lactobacillus plantarum and/or Lactobacillus acidophilus , more preferably L. plantarum.
- At least one microorganism belonging to the yeast group is a microorganism of the order Saccharomycetales of the family Saccharomycetaceae or of the order Schyzosaccharomycetales of the family Schyzosaccharomycetaceae, in particular those belonging to the genera Saccharomyces, Schyzosaccharomyces or Torulaspora.
- At least one microorganism belonging to the yeast group is Saccharomyces cerevisiae, Torulaspora delbrueckii, Saccharomyces boulardii and/or Schyzosaccharomyces pombe.
- At least one microorganism belonging to the group of acetic acid bacteria is a microorganism of the order Rhodospirillales of the family Acetobacteraceae, in particular those belonging to the genera Acetobacter, Gluconobacter and Komagataeibacter (also called Gluconacetobacter).
- Acetic acid bacteria can originate from cider vinegar or unpasteurized wine with an acidity level of 4% to 5%, preferably commercial cider vinegar, labeled "organic farming" according to the definition of the European Union.
- the addition of the acetic acid bacteria to the consortium is done by direct addition of an aliquot of vinegar in the composition comprising the other species of microorganisms.
- the consortium includes:
- At least one yeast belonging to the genus Saccharomyces, Schyzosaccharomyces or Torulaspora more preferably chosen from Saccharomyces cerevisiae, Saccharomyces boulardii, Schyzosaccharomyces pombe and Torulaspora delbrueckii, and
- acetic bacterium from cider vinegar or wine vinegar, preferably belonging to the genus Acetobacter, Gluconobacter or Komagataeibacter.
- a culture of microorganisms (in other words, a consortium comprising the microorganisms as described above) is prepared.
- This step advantageously makes it possible to activate and multiply the microorganisms while establishing a stable and balanced consortium.
- the different microorganisms that will be present in the consortium are introduced into a solution comprising a carbohydrate (otherwise called a "nutrient medium") and possibly also an aqueous extract of tea leaves in order to generate a microbial suspension.
- the suspension is then incubated for 1 to 21 days in order to prepare the culture of the microorganisms (in other words, the consortium).
- the solution comprises at least one carbohydrate, generally one or more mono- or disaccharides. It can be a pure sugar, such as sucrose, glucose or fructose, or a processed or co-produced product, such as molasses. Also, according to a preferential mode, the solution comprises a carbohydrate chosen from sucrose, glucose or fructose, molasses, or a mixture of one or more of these. Preferably, the carbohydrate is sucrose or a mixture of glucose and fructose. Preferably, at least one carbohydrate is present at a concentration comprised between 20 g/l and 100 g/l, preferably comprised between 50 to 95 g/l of solution. Preferably, the nutrient medium comprises sucrose, or a mixture of glucose and fructose, at a concentration of 50 g/l.
- the solution may also comprise an aqueous extract of tea leaves (Camellia sinensis).
- the aqueous extract is obtained from an infusion of tea leaves, preferably black tea leaves.
- the extract aqueous tea leaves may be a black tea infusion prepared with 2 g/l to 50 g/l of tea leaves, more preferably with 5 g/l to 10 g/l of tea leaves.
- the tea is prepared by adding dry leaves infused in water at a temperature of 70° C to 90° C for 10 to 60 min. Preferably, 5 g/l to 10 g/l of tea leaves are infused for 15 min at 80° C.
- the infusion can be used as is with the leaves, or more conveniently the aqueous phase is filtered. .
- the microorganisms can be introduced into the nutrient medium in dry and/or wet form; the inoculation rate may in particular be between 10 3 CFU/g and 10 5 CFU/g of solution.
- the microbial suspension can then be incubated between 12°C and 45°C, preferably between 25°C and 35°C, more preferably at 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, or 35°C even more preferably at 26°C.
- the incubation takes place in an open reactor, without the need to ensure aseptic conditions.
- the suspension can be incubated for 1 to 21 days, preferably for 1 to 10 days, more preferably for 3 to 4 days, even more preferably for 3 days or 4 days.
- the total flora in the suspension may be between 10 4 and 10 7 CFU/g.
- the consortium thus obtained is capable of reacting with a natural substrate, such as Longoza seeds, in an aqueous medium.
- a natural substrate such as Longoza seeds
- it is capable of directing the extractive fermentation of Longoza seeds, to make accessible, and possibly transform, a great diversity of the compounds it contains.
- the Longoza seeds are ground until a fine powder is obtained.
- the particles of this powder advantageously have an average size of between 0.01 and 1 mm, preferably between 100 ⁇ m and 1 mm, more preferentially between 250 and 500 ⁇ m, even more preferentially an average size of 500 ⁇ m.
- the seeds are raw.
- the seeds are dried before being ground.
- Step b) can be carried out either before, at the same time or after step a).
- the Longoza seed powder obtained in step b) is added to a fermentation medium, comprising the culture of the microorganisms obtained according to step a) as well as a carbohydrate, in order to obtain a fermentation mixture.
- the culture of microorganisms is added to the fermentation medium at a rate of between 10 2 CFU/g and 10 4 CFU/g of fermentation medium.
- the culture of microorganisms is added to the fermentation medium at a concentration of between 0.5% and 15% by weight based on the weight of fermentation medium, preferably between 0.75 and 10%, more preferably at 5% .
- the Longoza seeds in powder form are added to the fermentation medium at a concentration of between 1 and 75 g of seeds per liter of fermentation medium (g/L), preferably between 10 and 60 g/L, plus preferably between 12 and 50 g/L, even more preferably 12 g/L or 50 g/L.
- the Longoza seeds in powder form are added to the fermentation medium at a concentration of between 0.1 and 7.5%, preferably between 1 and 6%, more preferably between 1.2 and 5%, even more preferably at a concentration of 1, 2 or 5% by weight relative to the total volume of the fermentation medium.
- the fermentation medium also comprises a carbohydrate, preferably chosen from sucrose, glucose, fructose, molasses or a mixture of one or more of these.
- the solution can comprise an aqueous extract of tea leaves, as described above.
- the aqueous extract is obtained from an infusion of tea leaves, preferably black tea leaves.
- the latter can be heated before or after addition of the carbohydrate, for example at a temperature between 25° C. and 90° C., preferably 35° C.
- a temperature between 25° C. and 90° C. preferably 35° C.
- this is done before adding the culture of microorganisms or else at a temperature less than or equal to 45° C., preferably less than or equal to 35° C., if after adding the culture.
- the incubation takes place at a temperature between 12°C and 45°C, preferably between 25°C and 35°C, more preferably at 25°C, 26°C, 27°C, 28°C, 29°C. C, 30°C, 31°C, 32°C, 33°C, 34°C, or 35°C, even more preferably at 26°C.
- the incubation is carried out for a period of 2 to 20 days, preferably for 7 to 13 days, more preferably for 7, 8, 9, 10, 11, 12, or 13 days, even more preferably 10 days.
- the incubation takes place in an open reactor, without the need to ensure aseptic conditions.
- the incubation takes place at a humidity level of between 20% to 60%, preferably between 30% to 50%, more preferably 40%.
- step e) The fermentation mixture is then filtered during step e).
- filtration is meant here a step making it possible to separate the solid and liquid fractions.
- the solid fraction may in particular comprise the remaining Longoza seeds and/or microorganisms.
- filtration makes it possible to remove all the microorganisms present in the mixture, in order to obtain a fermented extract of sterile Longoza seeds.
- Filtration can be achieved by using one or more sieves and/or filters.
- step e) corresponds to one or more filtration steps, preferably comprising at least one sieving step and/or at least one sterilizing filtration step.
- step e) comprises a sieving step and a sterilizing filtration step.
- the sterilizing filtration is carried out on a filter having an average pore size of between 0.1 ⁇ m and 0.2 ⁇ m, preferably 0.2 ⁇ m.
- the sieving makes it possible to remove the powder debris.
- sterilizing filtration makes it possible to remove any cellular debris quickly and inexpensively.
- at least one of the filters is a cellulose filter.
- the process described above makes it possible to obtain a fermented extract of clarified Longoza seeds. However, in certain cases, it may be advantageous to carry out one or more additional steps, for example concentration or formulation.
- the process according to the invention can thus also comprise at least one additional step and subsequent to step e) of concentration or formulation.
- the method according to the invention further comprises, after step f) of filtration, one or more of the following steps aimed in particular at adapting the composition to a particular formulation:
- the fermentation process comprises a step f) of adding at least one preservative to the fermented extract of Longoza seeds.
- said preservative is chosen from butylene glycol, glycerin, propylene glycol, sodium benzoate benzoate and potassium sorbate, more preferentially glycerin.
- two or more preservatives may be added to the fermented Longoza seed extract.
- the preservative is added to the fermented Longoza seed extract of step f) at a final concentration of between 50 and 80%, preferably between 65 and 75%, more preferably 70%, by weight per relative to the total weight of the extract in the form of a solution.
- said preservative is selected from butylene glycol, glycerin and propylene glycol.
- the fermented extract of Longoza seeds is preferably stored at around 4°C (4 ⁇ 2°C) and/or in the dark at the end of step e) of filtration or at the end of any other step when an additional step is present after step e).
- the fermented extract of Longoza seeds is preferably stored at room temperature.
- the fermented extract of Longoza seeds is referenced under the international nomenclature, INCI: “Water, glycerin, Aframomum angustifolium seed extract, lactobacillus ferment lysate, yeast ferment extract”. This product contains in particular 1.2 to 1.65% by weight of dry extract of fermented extract of Longoza seeds in a water/glycerin mixture.
- the fermented extract of Longoza seeds has beneficial effects on the skin in vitro, making it possible in particular to increase the number and/or density of fibroblasts, as well as the expression of various proteins involved in the mechanical strength of the skin, its renewal and its elasticity, such as elafin, desmoglein 1 and loricrin.
- the fermented extract of Longoza seeds makes it possible to fight against the signs of skin aging linked to age and/or stress, in particular the loss of firmness and/or elasticity and the alteration of the barrier function of the skin.
- the fermented extract of Longoza seeds is used in an effective amount to obtain the desired effect. It can be used as it is or advantageously incorporated into a cosmetic composition suitable for topical application to keratin materials.
- the fermented extract of Longoza seeds is used as such or is present in a cosmetic composition.
- Another object of the invention relates to a cosmetic composition
- a cosmetic composition comprising, in a physiologically acceptable medium, a fermented extract of Longoza seeds according to the invention.
- cosmetic composition is meant any composition for cosmetic purposes, that is to say aesthetic, which can be brought into contact with the superficial parts of the human body and more particularly with keratin materials, in particular the skin and / or the human lips. .
- physiologically acceptable medium any excipient suitable for topical use, in contact with keratin materials, without risk of toxicity, incompatibility, instability and/or allergic response.
- keratin materials is meant the skin and/or its appendages, and more particularly the human skin and/or lips. In particular, it will be the skin of the face and/or of the neck and/or of the body, and of the lips.
- the keratin materials according to the invention are in particular healthy keratin materials (“healthy” subjects), that is to say not exhibiting disorders or disorders which would be part of a pathological state (“non-healthy” subjects, affected of a pathology). Reference will be made indiscriminately to healthy skin and/or lips or to healthy skin and/or lips in the rest of the description.
- the fermented extract of Longoza seeds is present in the composition of the invention in a content ranging from 0.0001% to 5%, preferably from 0.0005% to 2%, more preferably from 0.001% to 1% by weight of raw material (solution of fermented extract obtained according to the method described above) relative to the total weight of the composition.
- the fermented extract of Longoza seeds is present in the composition of the invention in a content ranging from 0.0000012% to 0.0825%, preferably from 0.000006% to 0.033%, more preferably from 0.000012 % to 0.0165% by weight of active ingredient (fermented extract of Longoza seeds) relative to the total weight of the composition.
- the additional ingredients advantageously used in the composition of the invention may be present in a content ranging from 0.0001% to 10%, preferably from 0.001% to 5% by weight (of raw material) relative to the total weight of the composition.
- the physiologically acceptable medium generally represents from 1 to 99% by weight, relative to the total weight of said composition.
- the physiologically acceptable medium of the composition according to the invention comprises water and optionally the preservative as defined above.
- said cosmetic composition comprising a fermented extract of Longoza seeds according to the invention is a composition for caring for and/or making up keratin materials, in particular the skin and/or the lips and in particular the face and/or neck skin.
- the cosmetic composition of the invention generally comprises, in addition to the fermented extract of Longoza seeds and the physiologically acceptable medium, one or more cosmetic excipients acceptable from those known to those skilled in the art with a view to obtaining a composition for the topical application, for example in the form of a milk, a cream, an ointment, a water-in-oil or oil-in-water emulsion, a balm, a stick, a gel, a lotion, a serum, or even a powder.
- the cosmetic composition of the invention may also be in the form of a patch or a mask, in particular a mask in the form of a thick cream, or else in the form of a cellulose mask soaked in fermented extract of seeds of Longoza or a composition containing it.
- said composition is in the form of a cream, emulsion, solution, suspension, gel, milk, lotion, or serum.
- the emulsion may be an oil-in-water or water-in-oil emulsion or multiple emulsion.
- the cosmetic composition of the invention may be in any galenic form suitable for topical application to keratin materials, in particular of the skin and/or of the lips and in particular of the skin of the face and/or of the neck comprising the fermented extract of Longoza seeds and at least one cosmetic ingredient chosen from antioxidants, perfumes, vitamins, thickening agents, emollient agents, moisturizing agents, anti-aging agents, lifting agents, tensing agents, plumping agents , soothing agents, antipollution agents, lightening or depigmenting agents, fillers, nacres and mixtures thereof.
- the cosmetic composition may also comprise at least one cosmetic adjuvant chosen from the group consisting of antioxidants, emollients, moisturizing agents, anti-aging agents, and mixtures thereof. .
- one or more cosmetically acceptable excipients will be selected from emulsifiers, polymers, surfactants, rheology agents, electrolytes, pH adjusters, antioxidants, preservatives, colorants, and their mixtures.
- the cosmetic composition may comprise hydrophilic gelling agents, antioxidants, preservatives and mixtures thereof.
- Cosmetic process also relates to a cosmetic process for caring for and/or making up keratin materials, in particular the skin and/or the lips and in particular the skin of the face and/or the neck, comprising the topical application on said keratin materials, of at least one layer of the fermented extract of Longoza seeds or of a cosmetic composition containing it as described according to the invention.
- the cosmetic process of the present invention is in particular intended to promote and/or stimulate epidermal renewal, desquamation of the skin, the vitality of the skin cells, and/or the cohesion of the skin cells, and/or prevent and/or reduce the signs of skin aging, in particular loss of firmness, loss of elasticity, loss of density, appearance of wrinkles and/or fine lines, dryness of the skin, alteration of the barrier function of the skin, the alteration of the suppleness of the skin and/or the alteration of the homogeneity or the radiance of the complexion.
- promoting and/or stimulating epidermal renewal is meant that the fermented extract of Longoza seeds is intended to promote keratinocyte differentiation.
- promoting and/or stimulating the desquamation of the skin we mean in particular that the fermented extract of Longoza seeds is intended to promote the renewal and development of cutaneous cells and tissues, in particular of the skin and/or the lips.
- promoting and/or stimulating the vitality of skin cells we mean in particular that the fermented extract of Longoza seeds is intended to promote the general condition of the skin, its radiance.
- the fermented extract of Longoza seeds is intended to reduce and/or delay the loss of firmness, the loss of elasticity, the loss of density, the dryness of the skin, loss of suppleness, and/or the appearance of wrinkles and/or fine lines.
- the fermented extract of Longoza seeds is intended to reduce and/or delay the appearance of imperfections or microreliefs of the skin, dark circles, a hazy, dull and/or uneven complexion.
- the fermented extract of Longoza seeds is intended to reduce and/or delay changes in the integrity of the skin, which can be associated, for example, with modifications of the interactions between cells and/or between cells and the extracellular matrix, likely to generate an alteration of the various functions of the skin barrier (eg: mechanical, water, antioxidant, etc.).
- said fermented extract of Longoza seeds according to the invention or said cosmetic composition containing it is applied to aged skin or showing signs of aging and/or skin exposed to stress, preferably aged skin or showing signs of aging.
- skin exposed to stress we mean that the skin is subjected to stress of endogenous or exogenous origin, in particular mechanical or chemical stress likely to induce unsightly non-pathological skin reactions - e.g. the skin is visibly tired and/or more sensitive to stimuli.
- the skins and lips to which the compositions of the invention are applied are healthy, that is to say not showing any disorders or disorders that would come under a pathological condition (“non-healthy” subjects, suffering from pathology).
- compositions comprising the fermented extract of Longoza seeds used in the context of the cosmetic process of the invention are those described above.
- Another object of the invention relates to the cosmetic use of the fermented extract of Longoza seeds according to the invention for topical application to keratin materials, in particular the skin and/or the lips and in particular the skin of the face and/or neck, as a cosmetic active ingredient intended to promote and/or stimulate epidermal renewal, desquamation of the skin, the vitality of the skin cells, and/or the cohesion of the skin cells, and/or to prevent and /or reduce the signs of skin aging, in particular loss of firmness, loss of elasticity, loss of density, appearance of wrinkles and/or fine lines, dryness of the skin, alteration of the barrier function of the skin, the alteration of the suppleness of the skin and/or the alteration of the homogeneity or the radiance of the complexion.
- the invention is illustrated by the following non-limiting examples.
- the % are expressed by weight of raw material relative to the total weight of the composition, unless otherwise indicated.
- microorganisms that are part of the consortium include:
- acetic bacterium belonging to the genus Acetobacter, Gluconobacter or Komagataeibacter.
- Raw Longoza seeds are crushed to obtain a powder composed of particles having an average size of about 250 to 500 pm.
- the tea is prepared from 5 g/l to 10 g/l of tea leaves infused for 10 to 60 min at 70°C to 90°C.
- the sucrose is then dissolved in the aqueous phase at a concentration between 20 g/l and 100 g/l, generally 50 g/l.
- Sucrose can in particular be replaced by a mixture of glucose and fructose.
- Fermentation of Longoza seeds was carried out according to a process comprising the following steps: a) incubation of a consortium of microorganisms in a solution comprising a carbohydrate and an aqueous extract of black tea leaves (i.e. the " nutrient medium”) at 26°C for 3 to 4 days in order to obtain a culture; b) the grinding of Longoza seeds in order to obtain a fine powder, as described below above ; c) the addition, in a fermentation medium comprising dechlorinated water and a carbohydrate, of:
- step a) the culture obtained in step a) at a concentration of 5% by weight relative to the weight of fermentation medium, in order to obtain a fermentation mixture; d) incubation of the fermentation mixture obtained in step c) in a fermenter at 26° C. for 10 days; e) filtering the fermentation mixture by coarse sieving followed by filtration through a cellulose filter having an average pore size of 0.2 ⁇ m to obtain a fermented Longoza seed extract, and, f) adding the glycerin with fermented extract of Longoza seeds at a final concentration of 70% by weight relative to the total weight.
- a fermented extract of Longoza seeds is obtained in the form of a solution at a concentration of 1.2 to 1.35% by weight of active ingredient of fermented Longoza seeds, 70% glycerin and 28.65 to 28, 8% water.
- a fermented extract of Longoza seeds is obtained in the form of a solution at a concentration of 1.35 to 1.65% by weight of active ingredient of fermented Longoza seeds, 70% glycerin and 28, 35 to 28.65% water.
- the fermented extract of Longoza seeds obtained from a concentration of Longoza seeds of 1.2% by weight relative to the liter of fermentation medium (i.e. 12 g/L) in step c) is named below the “L3” extract.
- the fermented extract of Longoza seeds obtained from a concentration of Longoza seeds of 5% by weight relative to the liter of fermentation medium (i.e. 50 g/L) in step c) is named below the extract “L2”.
- Example 2 Characterization of a fermented extract of Longoza seeds
- the assay was carried out on an agilent HPLC-D ⁇ D-MS 1260.
- the extract is injected at 0.02%, diluted to 1/ 50th in 0.1% HCOOH (weighing 20 pL qsp 1 mL)
- the parameters in the acquisition method cited above are as follows:
- Longoza seed fermented extract has been freeze-dried to reduce the amount of water.
- the mass injected was about 4 g.
- the fermented extract of Longoza seeds was dissolved in 11 ml lower phase + 6 ml upper phase and injected into the CPC column (303 mL column, FCPE300® instrument (Rousselet Robatel Kromaton)) via a 20 ml sample loop.
- the mobile phase was pumped upwards for 65 min.
- the column was extruded by switching the mode selector valve for 10 minutes.
- the flow rate was 20 mL/min and the column rotation speed was 1300 rpm.
- the two-phase solvent system is ethyl acetate/acetonitrile/water (3/3/4, v/v).
- the stationary phase corresponds to the lower phase of the two-phase solvent system (bottom-up mode) while the mobile phase corresponds to the upper phase of the two-phase solvent system.
- each 13 C NMR chemical shift cluster obtained by HCA was manually submitted to the structure search engine of the ACD/NMR Workbook Suite 2012 database management software (ACD/Labs, Ontario, Canada ) understanding the predicted chemical structures and shifts of low molecular weight natural products.
- 2D NMR experiments (HSQC, HMBC and COZY) were carried out on fractions containing supposedly identified compounds in order to confirm the molecular structures proposed by the database at the end of the dereplication process.
- the fermentation process generates a fermented Longoza seed extract having a very different composition from non-fermented Longoza extracts, for example an aqueous non-fermented Longoza extract extracted with 100% water.
- the fermented extract of Longoza seeds includes different organic acids, as shown in Table 1 below.
- KHN Normal Human Keratinocytes
- TPP150 flasks in supplemented Epilife medium.
- the KHNs are trypsinized at pre-confluence (0.05% Trypsin-EDTA, GIBCO-Invitrogen), and neutralized with a medium containing serum. They are then seeded in 96-well imaging plates (96-well p-plate, ibiTreat, Ibidi) at a rate of 10,000 cells per well.
- the KHNs are treated with the fermented extract of Longoza L2 or L3 seeds in complete Epilife medium containing 500 M of CaC (0.2 mL/well).
- the L2 and/or L3 extract was tested at a concentration of 0.02% and/or 0.1% v/v.
- the treatment is carried out for 3 or 5 days with replacement of the culture medium after 48 hours.
- the control conditions untreated
- the medium is replaced with new medium containing 500 ⁇ M of CaC.
- the cells are fixed with formalin (Formalin Solution 10% Neutral Buffered, Sigma) for 10 minutes then permeabilized with a solution of PBS-Triton 0.1% (Triton X-100, Sigma). They are then saturated with PBS/BSA 1% (PBS: phosphate-buffered saline solution BSA: bovine serum albumin), for 30 minutes and at room temperature. The 1% PBS/BS solution is then replaced with a solution of primary antibody corresponding to each labeled protein (see Table 2) diluted in PBS/1% BS. The plates are incubated overnight at 4°C.
- the cells After rinsing with PBS, the cells are covered with a solution of secondary antibody (anti-rabbit or anti-mouse goat antibody, Alexa Fluor 568 from Invitrogen) depending on the primary antibody to be targeted at 1/ 300th and of DAPI at 1/500th (4′,6′- diamidino -2-phenylindole, dihydrochloride, Invitrogen Molecular Probes) diluted in PBS/BSA 1%. The plates are incubated for one hour in the dark and at room temperature.
- secondary antibody anti-rabbit or anti-mouse goat antibody, Alexa Fluor 568 from Invitrogen
- PBS is deposited in each well at the rate of 1 mL. Plates are stored at 4°C in the dark until image acquisition.
- the plates are scanned with the “ArrayScan XTi” from Thermo Cellomics.
- DAPI filter XF53_386_23 Alexa Fluor 568: filter XF53_572_15
- the images were analyzed using “Spot detector” image analysis software, which detects the red labeling of the targeted protein, corresponding to its expression.
- the surface of the measurement area is delimited as being the entire surface of the image.
- the number of cells is determined by counting the nuclei by detecting the blue label.
- results can be expressed by:
- Loricrin is a structural protein expressed at the level of the horny envelope which contributes to the barrier function of the skin.
- the fermented extract of Longoza seeds significantly increases the expression of loricrin with a dose effect observed when the concentration of extract is increased (+41% for the L2 extract at a concentration of 0.02% and + 57% for the L2 extract at a concentration of 0.1%, p ⁇ 0.01, see Figure 1).
- filaggrin is a protein involved in the barrier function of the skin.
- the fermented extract of Longoza seeds increases the expression of filaggrin significantly with a dose effect observed when the concentration of extract is increased (+7.5% for the L3 extract at a concentration of 0.1% and +17.8% for the L2 extract at a concentration of 0.1%, p ⁇ 0.01, see Figure 2).
- Elafin is a protein involved in the skin barrier function. It also has an inhibitory effect on elastase, thus preventing the degradation of elastic fibers.
- the fermented extract of Longoza seeds significantly increases the expression of elafin with a dose effect observed when the concentration of extract is increased. Indeed, the expression is increased by +38.9% for the L3 extract at a concentration of 0.02% and by +52.6% for the L3 extract at a concentration of 0.1% (p ⁇ 0.05, see Figure 3). Similarly, the expression is increased by +37% for the L2 extract at a concentration of 0.02% and by +45.8% for the L2 extract at a concentration of 0.1% (p ⁇ 0 .05, see Figure 3).
- Kallikrein 5 is a protein involved in skin homeostasis and desquamation. It also contributes to the radiance of the skin.
- the fermented extract of Longoza seeds increases the expression of kallikrein 5 significantly (+15.2% for the L3 extract at a concentration of 0.02% and +11% for the L3 extract at a concentration 0.1%, p ⁇ 0.05, see Figure 4).
- Desmoglein 1 is a protein essential to the integrity of the epidermis, providing its structure through its adhesive function within intracellular junctions (desmosomes). It also promotes the differentiation of keratinocytes.
- the fermented extract of Longoza seeds increases the expression of desmoglein 1 significantly (+30.4% for the L3 extract at a concentration of 0.02% and +17% for the L2 extract at a concentration 0.02%, p ⁇ 0.01, see Figure 5).
- Transglutaminase is an enzyme involved in the cross-linking of structural proteins to form the horny envelope in the epidermis. It thus contributes to the barrier function of the skin.
- the fermented extract of Longoza seeds increases the expression of transglutaminase significantly (+73.8% for the L2 extract at a concentration of 0.1% and +97.6% for the L3 extract at a concentration of concentration of 0.1%, p ⁇ 0.01, see Figure 6).
- ZO-1 is an intercellular protein involved in the formation of tight junctions between skin cells. It thus contributes to the barrier function and the integrity of the skin.
- the fermented extract of Longoza seeds increases the expression of ZO-1 significantly (+25.8% for the L2 extract at a concentration of 0.1% and +49.7% for the L3 extract at 0.1% concentration, p ⁇ 0.01, see Figure 7).
- the extracts have positive effects on the expression of skin barrier markers such as elafin involved in the constitution of the horny envelope or desmoglein 1 constitutive of desmosomal junctions.
- the L3 extract increases the expression of kallikrein 5, involved in homeostasis and desquamation of the skin.
- the effect of the fermented Longoza seed extract according to the present invention on the elasticity, firmness, and cell density of the skin was evaluated in a stem cell-depleted skin model.
- the powders entering into the composition of the bio-ink were dissolved in calcium-free DMEM and placed under stirring at 37° C. overnight.
- cubes of dimensions 1.5 cm ⁇ 1.5 cm ⁇ 0.2 cm were printed with the inks containing the papillary fibroblasts. The height of these objects corresponded to two superimposed layers. Following this first printing, cubes of dimensions 1.5 cm ⁇ 1.5 cm ⁇ 0.1 cm (equivalent to 1 layer) were printed above the first cubes of 2 layers. These constructs were then placed for 1 hour in a solution of calcium and thrombin allowing the polymerization and consolidation of the bio-ink.
- the dermal equivalents were cultured in MCF (internal preparation from LabSkin Creations, medium adapted to the culture of fibroblasts) and placed in an incubator (37° C., 5% CO2) then cultured 7 days before the seeding of the sorted keratinocytes on their surface.
- the culture medium was renewed every 2 days.
- the keratinocytes were incubated for 15 minutes at +4° C. with the magnetic beads according to a defined cell/bead volume ratio. This mixture was then centrifuged and then the supernatant was discarded to get rid of the magnetic beads not bound to the cells of interest.
- the pellet of keratinocytes was resuspended in culture medium, and was passed over the magnetic columns installed on the magnet provided for this purpose.
- the column was unhooked from the magnetic support and rinsed, making it possible to harvest the cells expressing the surface marker CD71 (fraction depleted in stem cells) which were bound to the magnetic beads.
- the fractions enriched and depleted in cells were counted in order to calculate the CD71 ⁇ /CD71 + ratio.
- foreskin keratinocytes previously cultured were also trypsinized and counted to be seeded the same day on the dermis. These constitute the “young control”.
- the dermo-epidermal assemblies were cultured for 3 days in MCK medium allowing the proliferation of keratinocytes. They were then raised at the air/liquid interface in order to initiate epidermal differentiation. This final culturing step lasted a week in order to obtain pluristratified but not completely mature epidermis.
- the L2 or L3 extract was added to the culture medium.
- the medium was then filtered to avoid any risk of contamination.
- the extracts were applied to the cell cultures daily for the last 5 days of culture (cultures stopped at day 35).
- Alpha 6 anti-integrin labeling was performed on sections 5 and 20 micrometers thick. After heat unmasking, a saturation step in PBS/BSA 4% made it possible to block the aspecific antigenic sites.
- the cells were then incubated overnight with a primary antibody specific for the alpha 6 integrin antigen at 1/ 10,000th (rabbit monoclonal antibody, Abeam) then with an anti-rabbit Alexa-Fluor 568 secondary antibody diluted to 1 /1000 th (Thermo Fisher Scientific, MA, USA) and the dye nuclear Hoechst (Thermo Fisher Scientific). A negative control without primary antibody was carried out in parallel.
- the AFM used is a Resolve bioscope (Bruker) on which was mounted an epifluorescence microscope (Leica DMi8) allowing the realization of correlative studies (AFM/Fluorescence image).
- PeakForce® QNM/Fast-Force volume mode was used.
- the AFM probe that was chosen has a theoretical stiffness constant of 0.4N/m and a radius of curvature ⁇ 10nm. Before each use, the deflection sensitivity of the probe was measured on Saphir and its stiffness constant was also calibrated by the thermal noise method.
- the lever of the AFM was positioned on the Dermo-Epidermal Junction (DEJ) visible thanks to the anti-integrin alpha 6 immunostaining carried out on frozen sections.
- DEJ Dermo-Epidermal Junction
- a complete AFM analysis consisted of the acquisition of a force volume of the zone of interest (JDE) in aqueous conditions (PBS 1X).
- the fermented extract of Longoza L3 seeds by inducing an increase in the proliferative compartment at the basal level of the epidermis, makes it possible to obtain a stiffer and more strongly anchored JDE as well as thicker and proliferative epidermis which however, showed satisfactory differentiation.
- the fermented extract of Longoza seeds as prepared in Example 1 is formulated in the following illustrative and non-limiting compositions, prepared according to conventional cosmetic formulation methods.
- this composition provides an anti-aging action with beneficial effects on the firmness and/or elasticity of the skin.
- the serum is applied all over the face and especially on areas showing signs of aging.
- the serum comprising the fermented extract of Longoza seeds according to the invention promotes epidermal renewal, for elastic, firmer skin and a more even complexion.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a fermented extract of Longoza seeds, as well as to the preparation method thereof and to cosmetic compositions containing same. The fermented extract of Longoza seeds can in particular be used as an active ingredient to promote and/or stimulate epidermal renewal, desquamation of the skin, vitality of the skin cells, and/or cohesion of the skin cells, and/or to prevent and/or reduce the signs of skin ageing, in particular loss of firmness, loss of elasticity, loss of density, appearance of wrinkles and/or fine lines, dryness of the skin, alteration of the skin's barrier function, alteration of the skin's suppleness and/or alteration of the homogeneity or radiance of the complexion.
Description
DESCRIPTION DESCRIPTION
TITRE : Extrait fermenté de graines de Longoza TITLE: Fermented Longoza Seed Extract
DOMAINE DE L'INVENTION FIELD OF THE INVENTION
La présente invention concerne le domaine cosmétique et en particulier un extrait fermenté de graines de Longoza ainsi que le procédé de fermentation permettant de l’obtenir, une composition cosmétique contenant ledit extrait fermenté de graines de Longoza, et son utilisation dans un procédé cosmétique de soin et/ou de maquillage des matières kératiniques. The present invention relates to the cosmetic field and in particular to a fermented extract of Longoza seeds as well as the fermentation process for obtaining it, a cosmetic composition containing said fermented extract of Longoza seeds, and its use in a cosmetic care process. and/or for making up keratin materials.
ETAT DE LA TECHNIQUE STATE OF THE ART
On sait que le vieillissement est induit par des facteurs endogènes (ex : stress, hormones...) et exogènes (ex : température, climat, rayonnement UV, pollution atmosphérique, fumée de cigarette...) conduisant à un ralentissement et/ou une altération de différentes fonctions cellulaires. Au niveau de la peau, le vieillissement se traduit par différents signes cliniques, notamment par une diminution du renouvellement épidermique, une altération de la barrière cutanée, une perte de fermeté et d’élasticité de la peau, une diminution de l’épaisseur de la peau, l’apparition de rides ou ridules, l’apparition d’un teint moins homogène, et/ou une peau plus sèche. We know that aging is induced by endogenous (eg: stress, hormones, etc.) and exogenous (eg: temperature, climate, UV radiation, atmospheric pollution, cigarette smoke, etc.) factors leading to a slowdown and/or an alteration of various cellular functions. At the level of the skin, aging is manifested by various clinical signs, in particular by a reduction in epidermal renewal, an alteration of the cutaneous barrier, a loss of firmness and elasticity of the skin, a reduction in the thickness of the skin, the appearance of fine lines or wrinkles, the appearance of a less even complexion, and/or drier skin.
Il existe donc un besoin constant de trouver des agents capables de prévenir et/ou diminuer les signes du vieillissement cutané, notamment permettant de lutter contre les stress et/ou permettant de stimuler et/ou favoriser le renouvellement cutané ainsi que la vitalité des cellules cutanées. There is therefore a constant need to find agents capable of preventing and/or reducing the signs of skin aging, in particular making it possible to combat stress and/or making it possible to stimulate and/or promote skin renewal as well as the vitality of skin cells. .
De manière inattendue, la Demanderesse a mis en évidence les effets ‘anti-âge’ d’un extrait fermenté de graines de Longoza in vitro sur un modèle de peau. En effet, l’extrait fermenté de graines de Longoza permet avantageusement d’améliorer la structure de la peau, qui devient notamment plus épaisse, avec une organisation basale très nette et des jonctions dermo-épidermiques structurées. Par ailleurs, l’extrait fermenté de graines de Longoza permet avantageusement d’augmenter l’expression de diverses protéines impliquées dans la solidité mécanique de la peau ainsi que son renouvellement et son élasticité, telles que
l’élafine, la desmogléine 1 , la loricrine, la transglutaminase et la ZO-1 , favorisant in fine l’intégrité cellulaire et l’homéostasie des cellules de la peau. Ces effets permettent donc d’envisager l’utilisation de cet extrait fermenté de graines de Longoza pour prévenir et/ou diminuer les signes du vieillissement cutané. L’extrait fermenté de graines de Longoza est notamment utilisé selon l’invention comme actif cosmétique destiné à favoriser et/ou stimuler le renouvellement épidermique, la desquamation de la peau, la vitalité des cellules cutanées et/ou la cohésion des cellules cutanées, et/ou prévenir et/ou diminuer les signes du vieillissement cutané, notamment la perte de fermeté, la perte d’élasticité, la perte de densité, l’apparition de rides et/ou ridules, la sécheresse de la peau, l’altération de la fonction barrière de la peau, l’altération de la souplesse de la peau et/ou l’altération de l’homogénéité ou de l’éclat du teint. Unexpectedly, the Applicant demonstrated the 'anti-aging' effects of a fermented extract of Longoza seeds in vitro on a skin model. Indeed, the fermented extract of Longoza seeds advantageously makes it possible to improve the structure of the skin, which notably becomes thicker, with a very clear basal organization and structured dermo-epidermal junctions. Furthermore, the fermented extract of Longoza seeds advantageously makes it possible to increase the expression of various proteins involved in the mechanical solidity of the skin as well as its renewal and its elasticity, such as elafin, desmoglein 1 , loricrine, transglutaminase and ZO-1 , ultimately promoting cellular integrity and skin cell homeostasis. These effects therefore make it possible to consider the use of this fermented extract of Longoza seeds to prevent and/or reduce the signs of skin aging. The fermented extract of Longoza seeds is in particular used according to the invention as a cosmetic active ingredient intended to promote and/or stimulate epidermal renewal, desquamation of the skin, the vitality of the skin cells and/or the cohesion of the skin cells, and /or prevent and/or reduce the signs of skin aging, in particular loss of firmness, loss of elasticity, loss of density, appearance of wrinkles and/or fine lines, dryness of the skin, alteration of the barrier function of the skin, the alteration of the suppleness of the skin and/or the alteration of the homogeneity or the radiance of the complexion.
EXPOSE DE L'INVENTION DISCLOSURE OF THE INVENTION
Le premier objet de l’invention concerne donc un extrait fermenté de graines de Longoza comprenant une teneur en acide quinique comprise entre 0,05 et 2 % et une teneur en acide acétique comprise entre 5 et 15 %, en poids par rapport au poids d’extrait sec de l’extrait fermenté. The first object of the invention therefore relates to a fermented extract of Longoza seeds comprising a quinic acid content of between 0.05 and 2% and an acetic acid content of between 5 and 15%, by weight relative to the weight of dry extract of the fermented extract.
Un autre objet de l’invention porte sur un procédé de fermentation de graines de Longoza comprenant les étapes suivantes : a) l’incubation d’un consortium de micro-organismes dans une solution comprenant un glucide à une température comprise entre 17 et 38° C pendant 1 à 10 jours afin d’obtenir une culture de micro-organismes, ledit consortium comprenant au moins une bactérie lactique appartenant au genre Lactobacillus ou Pediococcus, au moins une levure appartenant au genre Saccharomyces, Schyzosaccharomyces ou Torulaspora, et au moins une bactérie acétique appartenant au genre Àcetobacter, Gluconobacter ou Komagataeibacter ; b) le broyage de graines de Longoza afin d’obtenir une poudre composée de particules ayant une taille moyenne comprise entre 100 pm et 1 mm ; c) l’ajout de ladite poudre dans un milieu fermentaire comprenant la culture de microorganismes afin d’obtenir un mélange de fermentation, ledit milieu fermentaire comprenant un glucide choisi parmi le saccharose, le glucose, le fructose, la mélasse ou un mélange d’un ou plusieurs de ceux-ci, d) l’incubation du mélange de fermentation à une température comprise entre 25 et
35°C pendant 7 à 13 jours, et e) la filtration du mélange de fermentation afin d’obtenir un extrait fermenté de graines de Longoza. Another object of the invention relates to a process for the fermentation of Longoza seeds comprising the following steps: a) the incubation of a consortium of microorganisms in a solution comprising a carbohydrate at a temperature between 17 and 38° C for 1 to 10 days in order to obtain a culture of microorganisms, said consortium comprising at least one lactic acid bacterium belonging to the genus Lactobacillus or Pediococcus, at least one yeast belonging to the genus Saccharomyces, Schyzosaccharomyces or Torulaspora, and at least one bacterium acetic acid belonging to the genus Acetobacter, Gluconobacter or Komagataeibacter; b) the grinding of Longoza seeds in order to obtain a powder composed of particles having an average size of between 100 μm and 1 mm; c) adding said powder to a fermentation medium comprising the culture of microorganisms in order to obtain a fermentation mixture, said fermentation medium comprising a carbohydrate chosen from sucrose, glucose, fructose, molasses or a mixture of one or more of these, d) incubating the fermentation mixture at a temperature between 25 and 35°C for 7 to 13 days, and e) filtering the fermentation mixture to obtain a fermented extract of Longoza seeds.
Aussi, un autre objet de l’invention porte sur un extrait fermenté de graines de Longoza obtenu par le procédé tel que décrit selon l’invention. Also, another object of the invention relates to a fermented extract of Longoza seeds obtained by the method as described according to the invention.
L’invention concerne également une composition cosmétique comprenant, dans un milieu physiologiquement acceptable, un extrait fermenté de graines de Longoza. The invention also relates to a cosmetic composition comprising, in a physiologically acceptable medium, a fermented extract of Longoza seeds.
Un autre objet de l’invention concerne un procédé cosmétique de soin et/ou maquillage des matières kératiniques, en particulier de la peau et/ou des lèvres, comprenant l’application sur lesdites matières kératiniques, d’au moins une couche de la composition cosmétique telle que décrite selon l’invention. Another object of the invention relates to a cosmetic process for caring for and/or making up keratin materials, in particular the skin and/or the lips, comprising the application to said keratin materials of at least one layer of the composition cosmetic as described according to the invention.
L’invention concerne enfin l’utilisation cosmétique d’un extrait fermenté de graines de Longoza selon l’invention comme actif pour favoriser et/ou stimuler le renouvellement épidermique, la desquamation de la peau, la vitalité des cellules cutanées, et/ou la cohésion des cellules cutanées, et/ou prévenir et/ou diminuer les signes du vieillissement cutané, notamment la perte de fermeté, la perte d’élasticité, la perte de densité, l’apparition de rides et/ou ridules, la sécheresse de la peau, l’altération de la fonction barrière de la peau, l’altération de la souplesse de la peau et/ou l’altération de l’homogénéité ou de l’éclat du teint. The invention finally relates to the cosmetic use of a fermented extract of Longoza seeds according to the invention as an active ingredient for promoting and/or stimulating epidermal renewal, desquamation of the skin, the vitality of skin cells, and/or the cohesion of skin cells, and/or preventing and/or reducing the signs of skin aging, in particular loss of firmness, loss of elasticity, loss of density, appearance of wrinkles and/or fine lines, dryness of the skin, the alteration of the barrier function of the skin, the alteration of the suppleness of the skin and/or the alteration of the homogeneity or the radiance of the complexion.
DESCRIPTION DES FIGURES DESCRIPTION OF FIGURES
[Fig. 1] Effet de l’extrait fermenté de graines de Longoza sur l’expression de la loricrine[Fig. 1] Effect of fermented Longoza seed extract on loricrin expression
[Fig. 2] Effet de l’extrait fermenté de graines de Longoza sur l’expression de la filaggrine[Fig. 2] Effect of Fermented Longoza Seed Extract on Filaggrin Expression
[Fig. 3] Effet de l’extrait fermenté de graines de Longoza sur l’expression de l’élafine[Fig. 3] Effect of Fermented Longoza Seed Extract on Elafin Expression
[Fig. 4] Effet de l’extrait fermenté de graines de Longoza sur l’expression de la kallicréine[Fig. 4] Effect of Fermented Longoza Seed Extract on Kallikrein Expression
5 5
[Fig. 5] Effet de l’extrait fermenté de graines de Longoza sur l’expression de la desmogléine 1 [Fig. 5] Effect of Fermented Longoza Seed Extract on Desmoglein 1 Expression
[Fig. 6] Effet de l’extrait fermenté de graines de Longoza sur l’expression de la transglutaminase [Fig. 6] Effect of Fermented Longoza Seed Extract on Transglutaminase Expression
[Fig. 7] Effet de l’extrait fermenté de graines de Longoza sur l’expression de ZO-1
[Fig. 8] Analyse histologique de l’effet de l’extrait fermenté de graines de Longoza sur un modèle de la peau [Fig. 7] Effect of Fermented Longoza Seed Extract on ZO-1 Expression [Fig. 8] Histological analysis of the effect of Longoza seed fermented extract on a skin model
[Fig. 9] Effet de l’extrait fermenté de graines de Longoza sur le module élastique de la peau [Fig. 9] Effect of Fermented Longoza Seed Extract on Elastic Modulus of Skin
DESCRIPTION DETAILLEE DE L'INVENTION DETAILED DESCRIPTION OF THE INVENTION
Aframomum ançustifolium ou Longoza Aframomum ansustifolium or Longoza
Originaire de Madagascar, le Longoza, est un fruit de [’Aframomum an ustifolium, une plante de la famille du gingembre. Cette plante se caractérise par une régénération exceptionnelle par la racine puisqu’elle croit même après coupes et brûlis. Elle fait partie des plantes pionnières qui repoussent sur les terres brûlées lors des feux de forêts à Madagascar. Originally from Madagascar, the Longoza is a fruit of ['Aframomum an ustifolium, a plant of the ginger family. This plant is characterized by an exceptional regeneration by the root since it grows even after cutting and burning. It is one of the pioneer plants that grow back on land burned during forest fires in Madagascar.
Dans le contexte de la présente invention, l’extrait fermenté d’ Aframomum an ustifolium ou Longoza est obtenu à partir des graines de la plante Aframomum an ustifolium ou Longoza. Bien qu’on utilise l’expression « graines de Longoza » ici par simplification, celle- ci signifie évidemment indifféremment des graines d’ Aframomum an ustifolium ou de Longoza. In the context of the present invention, the fermented extract of Aframomum an ustifolium or Longoza is obtained from the seeds of the Aframomum an ustifolium or Longoza plant. Although we use the expression “seeds of Longoza” here for simplification, this obviously means indifferently seeds of Aframomum an ustifolium or Longoza.
Extrait fermenté de graines de Longoza Longoza seed fermented extract
Des graines de Longoza sont utilisées dans un procédé de fermentation afin de générer un extrait fermenté de graines de Longoza, objet de la présente invention. Longoza seeds are used in a fermentation process in order to generate a fermented extract of Longoza seeds, object of the present invention.
Il est précisé que dans la présente description, l’expression « extrait fermenté » désigne le produit issu du procédé de fermentation par la fermentation, avec ou sans filtration, donc aussi bien avec que sans la biomasse microbienne du milieu fermentaire, ainsi que tout produit ayant subi des étapes supplémentaires, tel qu’une étape de formulation (par ex par ajout d’un conservateur). It is specified that in the present description, the expression "fermented extract" designates the product resulting from the fermentation process by fermentation, with or without filtration, therefore both with and without the microbial biomass of the fermentation medium, as well as any product having undergone additional steps, such as a formulation step (eg by adding a preservative).
Selon un mode particulier, l’extrait fermenté de graines de Longoza selon l’invention se présente sous la forme d’une solution aqueuse d’extrait fermenté comprenant l’extrait sec fermenté, de l’eau et un conservateur. L’extrait fermenté sous forme de solution aqueuse est également nommé ‘matière première’ dans la description, par opposition à ‘matière sèche’ ou extrait sec fermenté.
Selon un mode particulier, la solution aqueuse d’extrait fermenté comprend l’extrait fermenté en une teneur active (matière sèche) allant de 0,5 à 3 % en poids, notamment 1 à 2 % en poids et en particulier 1 ,2 à 1 ,7 % en poids de matière active par rapport au poids total de matière première (solution aqueuse d’extrait fermenté), de l’eau et un conservateur, de préférence la glycérine. La teneur en eau ira généralement de 20 à 40 % en poids, notamment de 25 à 30 % en particulier de 27 à 29 % en poids par rapport au poids total de matière première (solution aqueuse d’extrait fermenté) et la teneur en conservateur (par ex : glycérine) ira généralement de 60 à 80 % en poids, notamment de 65 à 75 % en poids, en particulier 70 % en poids par rapport au poids total de matière première (solution aqueuse d’extrait fermenté). According to a particular embodiment, the fermented extract of Longoza seeds according to the invention is in the form of an aqueous solution of fermented extract comprising the fermented dry extract, water and a preservative. The fermented extract in the form of an aqueous solution is also called 'raw material' in the description, as opposed to 'dry matter' or fermented dry extract. According to a particular embodiment, the aqueous solution of fermented extract comprises the fermented extract in an active content (dry matter) ranging from 0.5 to 3% by weight, in particular 1 to 2% by weight and in particular 1.2 to 1.7% by weight of active material relative to the total weight of raw material (aqueous solution of fermented extract), water and a preservative, preferably glycerin. The water content will generally range from 20 to 40% by weight, in particular from 25 to 30% in particular from 27 to 29% by weight relative to the total weight of raw material (aqueous solution of fermented extract) and the preservative content (for example: glycerin) will generally range from 60 to 80% by weight, in particular from 65 to 75% by weight, in particular 70% by weight relative to the total weight of raw material (aqueous solution of fermented extract).
Ainsi, l’invention porte également sur un extrait fermenté de graines de Longoza sous la forme d’une solution comprenant 1 à 2 % en poids de matière active d’extrait fermenté de graines de Longoza, 65 à 75 % en poids de glycérine et 25 à 30 % en poids d’eau. Thus, the invention also relates to a fermented extract of Longoza seeds in the form of a solution comprising 1 to 2% by weight of active ingredient of fermented extract of Longoza seeds, 65 to 75% by weight of glycerin and 25 to 30% by weight of water.
De préférence, la solution aqueuse d’extrait fermenté, autrement nommée ‘matière première’ dans la caractérisation qui est illustrée ci-après, comprend 1 ,2 à 1 ,65 % en matière active (matière sèche) d’extrait fermenté, 70 % de glycérine et 28,35 à 28,8 % d’eau par rapport au poids total de matière première (solution aqueuse d’extrait fermenté). Selon un mode particulier, la solution aqueuse d’extrait fermenté, autrement nommée ‘matière première’ dans la caractérisation qui est illustrée ci-après, comprend 1 ,2 à 1 ,35 % en matière active (matière sèche) d’extrait fermenté, 70 % de glycérine et 28,65 à 28,8 % d’eau par rapport au poids total de matière première (solution aqueuse d’extrait fermenté). Selon un autre mode particulier, la solution aqueuse d’extrait fermenté, autrement nommée ‘matière première’ dans la caractérisation qui est illustrée ci-après, comprend 1 ,35 à 1 ,65 % en matière active (matière sèche) d’extrait fermenté, 70 % de glycérine et 28,35 à 28,65 % d’eau par rapport au poids total de matière première (solution aqueuse d’extrait fermenté). Preferably, the aqueous solution of fermented extract, otherwise called 'raw material' in the characterization which is illustrated below, comprises 1.2 to 1.65% in active matter (dry matter) of fermented extract, 70% of glycerine and 28.35 to 28.8% of water relative to the total weight of raw material (aqueous solution of fermented extract). According to a particular mode, the aqueous solution of fermented extract, otherwise called 'raw material' in the characterization which is illustrated below, comprises 1.2 to 1.35% in active matter (dry matter) of fermented extract, 70% glycerin and 28.65 to 28.8% water relative to the total weight of raw material (aqueous solution of fermented extract). According to another particular mode, the aqueous solution of fermented extract, otherwise called 'raw material' in the characterization which is illustrated below, comprises 1.35 to 1.65% in active matter (dry matter) of fermented extract , 70% glycerin and 28.35 to 28.65% water relative to the total weight of raw material (aqueous solution of fermented extract).
Selon un mode particulier, l’extrait fermenté de graines de Longoza comprend une teneur en acide quinique supérieure à 0,005 %, de préférence comprise entre 0,005 et 10 %, et une teneur en acide acétique supérieure à 0,5 %, de préférence comprise entre 0,5 et 25 %, en poids par rapport au poids d’extrait sec (matière sèche) de l’extrait fermenté. De préférence, l’extrait fermenté de graines de Longoza comprend une teneur en acide quinique comprise entre 0,01 et 5 %, plus préférentiellement comprise entre 0,05 et 2 % en poids par rapport au poids d’extrait sec de l’extrait fermenté. De préférence, l’extrait
fermenté de graines de Longoza comprend une teneur en acide acétique comprise entre 1 et 20 %, plus préférentiellement comprise entre 5 et 15 % en poids en poids par rapport au poids d’extrait sec de l’extrait fermenté. According to a particular mode, the fermented extract of Longoza seeds comprises a quinic acid content greater than 0.005%, preferably between 0.005 and 10%, and an acetic acid content greater than 0.5%, preferably between 0.5 and 25%, by weight relative to the weight of dry extract (dry matter) of the fermented extract. Preferably, the fermented extract of Longoza seeds comprises a quinic acid content of between 0.01 and 5%, more preferably between 0.05 and 2% by weight relative to the dry extract weight of the extract fermented. Preferably, the extract fermented Longoza seeds comprises an acetic acid content of between 1 and 20%, more preferably between 5 and 15% by weight by weight relative to the dry extract weight of the fermented extract.
L’extrait fermenté de graines de Longoza peut comprendre d’autres acides organiques, tels que l’acide citrique, l’acide gluconique, l’acide lactique, l’acide malique, et l’acide succinique. Aussi, l’extrait fermenté de graines de Longoza peut notamment comprendre : Longoza seed fermented extract may include other organic acids, such as citric acid, gluconic acid, lactic acid, malic acid, and succinic acid. Also, the fermented extract of Longoza seeds may include:
- une teneur en acide citrique comprise entre 0,01 et 5 %, de préférence entre 0,05 et 2 % plus préférentiellement entre 0,1 et 1 %, encore plus préférentiellement entre 0,2 et 0,4 % en poids par rapport au poids d’extrait sec de l’extrait fermenté, - a citric acid content of between 0.01 and 5%, preferably between 0.05 and 2%, more preferably between 0.1 and 1%, even more preferably between 0.2 and 0.4% by weight relative the dry extract weight of the fermented extract,
- une teneur en acide gluconique supérieure à 0,5 %, de préférence comprise entre 0,5 et 25 %, plus préférentiellement entre 1 et 20 %, encore plus préférentiellement entre 1 et 15 % en poids par rapport au poids d’extrait sec de l’extrait fermenté, - a gluconic acid content greater than 0.5%, preferably between 0.5 and 25%, more preferably between 1 and 20%, even more preferably between 1 and 15% by weight relative to the weight of dry extract fermented extract,
- une teneur en acide lactique comprise entre 0,001 et 10 %, de préférence entre 0,005 et 5 %, plus préférentiellement entre 0,01 et 2 % plus préférentiellement compris entre 0,01 et 1 ,5 % en poids par rapport au poids d’extrait sec de l’extrait fermenté, - a lactic acid content of between 0.001 and 10%, preferably between 0.005 and 5%, more preferably between 0.01 and 2%, more preferably between 0.01 and 1.5% by weight relative to the weight of dry extract of the fermented extract,
- une teneur en acide malique comprise entre 0,001 et 5 %, de préférence entre 0,005 et 1 %, plus préférentiellement entre 0,008 et 0,5 % en poids par rapport au poids d’extrait sec de l’extrait fermenté, et/ou - a malic acid content of between 0.001 and 5%, preferably between 0.005 and 1%, more preferably between 0.008 and 0.5% by weight relative to the dry extract weight of the fermented extract, and/or
- une teneur en acide succinique comprise entre 0,001 et 5 %, de préférence entre 0,005 et 1 %, plus préférentiellement entre 0,01 et 0,05 % en poids par rapport au poids d’extrait sec de l’extrait fermenté. - a succinic acid content of between 0.001 and 5%, preferably between 0.005 and 1%, more preferably between 0.01 and 0.05% by weight relative to the dry extract weight of the fermented extract.
De préférence, l’extrait fermenté de graines de Longoza ne comprend pas d’acide glucuronique ou d’acide propionique. Preferably, the fermented Longoza seed extract does not include glucuronic acid or propionic acid.
L’extrait fermenté de graines de Longoza peut également comprendre un ou plusieurs conservateurs. Par « conservateur » on entend un composé qui a pour but de préserver la composition de l’extrait ou la cosmétique le contenant de toute altération physico-chimique et/ou microbienne. De préférence, au moins un conservateur est choisi parmi le butylène glycol, la glycérine, le propylène glycol, le benzoate de sodium benzoate et le sorbate de potassium, plus préférentiellement la glycérine. L’extrait fermenté peut notamment comprendre un ou plusieurs conservateur(s) à une concentration finale comprise entre 60 et 80 %, préférentiellement entre 65 et 75 %, plus préférentiellement 70 % en poids par rapport
au poids total, de préférence au moins un des conservateurs décrits ci-dessus choisi parmi le butylène glycol, la glycérine et le propylène glycol. The fermented Longoza seed extract may also include one or more preservatives. By “preservative” is meant a compound whose purpose is to preserve the composition of the extract or the cosmetic containing it from any physico-chemical and/or microbial alteration. Preferably, at least one preservative is chosen from butylene glycol, glycerin, propylene glycol, sodium benzoate benzoate and potassium sorbate, more preferentially glycerin. The fermented extract may in particular comprise one or more preservative(s) at a final concentration of between 60 and 80%, preferably between 65 and 75%, more preferably 70% by weight relative by total weight, preferably at least one of the preservatives described above chosen from butylene glycol, glycerin and propylene glycol.
Procédé de fermentation Fermentation process
Cet extrait fermenté de graines de Longoza est obtenu par un procédé de fermentation comprenant des étapes de : a) incubation d’un consortium de micro-organismes dans une solution comprenant un glucide et éventuellement en outre un extrait aqueux de feuilles de thé à une température comprise entre 17 à 38°C afin d’obtenir une culture de micro-organismes ; b) le broyage de graines d’Aframomum angustifolium ou Longoza afin d’obtenir une poudre fine ; c) ajout de ladite poudre dans un milieu fermentaire comprenant la culture de microorganismes et un glucide afin d’obtenir un mélange de fermentation ; c) incubation du mélange de fermentation à une température comprise entre 12 et 42° C pendant 2 à 20 jours ; d) filtration du mélange de fermentation, afin d’obtenir un extrait fermenté de graines de Longoza ; et, optionnellement, e) ajout d’au moins un conservateur. This fermented extract of Longoza seeds is obtained by a fermentation process comprising steps of: a) incubation of a consortium of microorganisms in a solution comprising a carbohydrate and optionally in addition an aqueous extract of tea leaves at a temperature between 17 and 38°C in order to obtain a culture of microorganisms; b) grinding seeds of Aframomum angustifolium or Longoza to obtain a fine powder; c) adding said powder to a fermentation medium comprising the culture of microorganisms and a carbohydrate in order to obtain a fermentation mixture; c) incubation of the fermentation mixture at a temperature between 12 and 42° C. for 2 to 20 days; d) filtration of the fermentation mixture, in order to obtain a fermented extract of Longoza seeds; and, optionally, e) adding at least one preservative.
Par « procédé de fermentation » on entend un procédé permettant d’obtenir un extrait fermenté de graines de Longoza par la mise en culture d’un consortium des micro-organismes tel que défini ici dans un milieu contenant un glucide et permettant leur croissance. La fermentation peut avoir lieu dans des conditions de culture discontinue (en « batch »), de culture continue, ou en continu-discontinu (en « Fed batch »). La fermentation peut être réalisée en aérobie, micro-aérobie et/ou anaérobie. By “fermentation process” is meant a process making it possible to obtain a fermented extract of Longoza seeds by culturing a consortium of microorganisms as defined here in a medium containing a carbohydrate and allowing their growth. The fermentation can take place under conditions of discontinuous culture (in “batch”), of continuous culture, or in continuous-discontinuous (in “Fed batch”). Fermentation can be carried out aerobic, micro-aerobic and/or anaerobic.
Par « consortium de micro-organismes » on entend un assemblage d’au moins trois espèces de micro-organismes pouvant coexister de manière stable et reproductible. By "consortium of microorganisms" is meant an assembly of at least three species of microorganisms that can coexist in a stable and reproducible manner.
Avantageusement, les micro-organismes permettent d’associer des activités complémentaires. À titre d’exemple non-limitatif, l’utilisation ou assimilation d’une source de carbone par une première espèce permet de produire des métabolites pouvant ensuite être métabolisés par une deuxième espèce.
Le consortium de micro-organismes selon la présente invention comprend : i) au moins un micro-organisme appartenant au groupe des bactéries lactiques, ii) au moins un micro-organisme appartenant au groupe des levures, et iii) au moins un micro-organisme appartenant au groupe des bactéries acétiques. Advantageously, the microorganisms make it possible to combine complementary activities. By way of non-limiting example, the use or assimilation of a carbon source by a first species makes it possible to produce metabolites which can then be metabolized by a second species. The consortium of microorganisms according to the present invention comprises: i) at least one microorganism belonging to the group of lactic acid bacteria, ii) at least one microorganism belonging to the group of yeasts, and iii) at least one microorganism belonging to the group of acetic acid bacteria.
De préférence, au moins un micro-organisme appartenant au groupe des bactéries lactiques est un micro-organisme de l’ordre des Lactobacillales de la famille des Lactobacillaceae, notamment ceux appartenant aux genres Lactobacillus et Pediococcus, tel que Lactobacillus plantarum et/ou Lactobacillus acidophilus, plus préférentiellement L. plantarum. Preferably, at least one microorganism belonging to the group of lactic acid bacteria is a microorganism of the order Lactobacillales of the Lactobacillaceae family, in particular those belonging to the genera Lactobacillus and Pediococcus, such as Lactobacillus plantarum and/or Lactobacillus acidophilus , more preferably L. plantarum.
De préférence, au moins un micro-organisme appartenant au groupe des levures est un micro-organisme de l’ordre des Saccharomycetales de la famille des Saccharomycetaceae ou de l’ordre des Schyzosaccharomycetales de la famille des Schyzosaccharomycetaceae, notamment ceux appartenant aux genres Saccharomyces, Schyzosaccharomyces ou Torulaspora. Preferably, at least one microorganism belonging to the yeast group is a microorganism of the order Saccharomycetales of the family Saccharomycetaceae or of the order Schyzosaccharomycetales of the family Schyzosaccharomycetaceae, in particular those belonging to the genera Saccharomyces, Schyzosaccharomyces or Torulaspora.
De préférence, au moins un micro-organisme appartenant au groupe des levures est Saccharomyces cerevisiae, Torulaspora delbrueckii, Saccharomyces boulardii et/ou Schyzosaccharomyces pombe. Preferably, at least one microorganism belonging to the yeast group is Saccharomyces cerevisiae, Torulaspora delbrueckii, Saccharomyces boulardii and/or Schyzosaccharomyces pombe.
De préférence, au moins un micro-organisme appartenant au groupe des bactéries acétiques est un micro-organisme de l’ordre des Rhodospirillales de la famille des Àcetobacteraceae, notamment ceux appartenant aux genres Acetobacter, Gluconobacter et Komagataeibacter (aussi appelé Gluconacetobacter). Les bactéries acétiques peuvent être originaires d'un vinaigre de cidre ou de vin non pasteurisé ayant un taux d'acidité de 4 % à 5 %, de préférence d’un vinaigre de cidre du commerce, labélisés « Agriculture biologique » selon la définition de l'Union Européenne. De préférence, l’ajout des bactéries acétiques au consortium se fait par ajout direct d’un aliquot de vinaigre dans la composition comprenant les autres espèces de micro-organismes. Il existe dans les vinaigres, à côté des bactéries acétiques dominantes, une flore indigène naturelle complexe dont une partie va pouvoir cohabiter avec les microorganismes ajoutés. Une autre partie va péricliter lors de l'établissement du consortium, de la même manière que le développement en symbiose de l’ensemble des micro-organismes formant le consortium empêche le développement des espèces indésirables, dont les espèces pathogènes.
Selon un mode préférentiel, le consortium comprend : Preferably, at least one microorganism belonging to the group of acetic acid bacteria is a microorganism of the order Rhodospirillales of the family Acetobacteraceae, in particular those belonging to the genera Acetobacter, Gluconobacter and Komagataeibacter (also called Gluconacetobacter). Acetic acid bacteria can originate from cider vinegar or unpasteurized wine with an acidity level of 4% to 5%, preferably commercial cider vinegar, labeled "organic farming" according to the definition of the European Union. Preferably, the addition of the acetic acid bacteria to the consortium is done by direct addition of an aliquot of vinegar in the composition comprising the other species of microorganisms. In vinegars, alongside the dominant acetic bacteria, there is a complex natural indigenous flora, part of which will be able to cohabit with the added microorganisms. Another part will collapse during the establishment of the consortium, in the same way as the development in symbiosis of all the micro-organisms forming the consortium prevents the development of undesirable species, including pathogenic species. According to a preferential mode, the consortium includes:
- au moins une bactérie lactique appartenant au genre Lactobacillus ou Pediococcus, plus préférentiellement choisie parmi Lactobacillus plantarum et Lactobacillus acidophilus, - at least one lactic acid bacterium belonging to the genus Lactobacillus or Pediococcus, more preferably chosen from Lactobacillus plantarum and Lactobacillus acidophilus,
- au moins une levure appartenant au genre Saccharomyces, Schyzosaccharomyces ou Torulaspora plus préférentiellement choisie parmi Saccharomyces cerevisiae, Saccharomyces boulardii, Schyzosaccharomyces pombe et Torulaspora delbrueckii, et- at least one yeast belonging to the genus Saccharomyces, Schyzosaccharomyces or Torulaspora more preferably chosen from Saccharomyces cerevisiae, Saccharomyces boulardii, Schyzosaccharomyces pombe and Torulaspora delbrueckii, and
- au moins une bactérie acétique provenant d’un vinaigre de cidre ou d'un vinaigre de vin, préférentiellement appartenant au genre Acetobacter, Gluconobacter ou Komagataeibacter. - at least one acetic bacterium from cider vinegar or wine vinegar, preferably belonging to the genus Acetobacter, Gluconobacter or Komagataeibacter.
Étape a) : préparation d’une culture de micro-organismes Step a): preparation of a culture of microorganisms
Selon une première étape, a), du procédé, une culture de micro-organismes (autrement dit, un consortium comprenant les micro-organismes tels que décrits ci-dessus) est préparée. Cette étape permet avantageusement d’activer et faire multiplier les micro-organismes tout en établissant un consortium stable et équilibré. Lors de cette étape, les différents microorganismes qui seront présents dans le consortium sont introduits dans une solution comprenant un glucide (autrement appelé un « milieu nutritif ») et éventuellement en outre un extrait aqueux de feuilles de thé afin de générer une suspension microbienne. La suspension est ensuite incubée pendant 1 à 21 jours afin de préparer la culture des microorganismes (autrement dit, le consortium). According to a first step, a), of the method, a culture of microorganisms (in other words, a consortium comprising the microorganisms as described above) is prepared. This step advantageously makes it possible to activate and multiply the microorganisms while establishing a stable and balanced consortium. During this step, the different microorganisms that will be present in the consortium are introduced into a solution comprising a carbohydrate (otherwise called a "nutrient medium") and possibly also an aqueous extract of tea leaves in order to generate a microbial suspension. The suspension is then incubated for 1 to 21 days in order to prepare the culture of the microorganisms (in other words, the consortium).
La solution comprend au moins un glucide, généralement un ou plusieurs mono- ou disaccharides. Il peut s'agir d’un sucre pur, tel que le saccharose, le glucose ou le fructose, ou bien d'un produit transformé ou coproduit, tel que de la mélasse. Aussi, selon un mode préférentiel, la solution comprend un glucide choisi parmi le saccharose, le glucose ou le fructose, la mélasse, ou un mélange d’un ou plusieurs de ceux-ci. De préférence, le glucide est le saccharose ou un mélange de glucose et de fructose. De préférence, au moins un glucide est présent à une concentration comprise entre 20 g/l et 100 g/l, de préférence comprise entre 50 à 95 g/l de solution. De préférence, le milieu nutritif comprend le saccharose, ou un mélange de glucose et de fructose, à une concentration de 50 g/l. The solution comprises at least one carbohydrate, generally one or more mono- or disaccharides. It can be a pure sugar, such as sucrose, glucose or fructose, or a processed or co-produced product, such as molasses. Also, according to a preferential mode, the solution comprises a carbohydrate chosen from sucrose, glucose or fructose, molasses, or a mixture of one or more of these. Preferably, the carbohydrate is sucrose or a mixture of glucose and fructose. Preferably, at least one carbohydrate is present at a concentration comprised between 20 g/l and 100 g/l, preferably comprised between 50 to 95 g/l of solution. Preferably, the nutrient medium comprises sucrose, or a mixture of glucose and fructose, at a concentration of 50 g/l.
Selon un mode particulier, la solution peut comprendre en outre un extrait aqueux de feuilles de thé (Camellia sinensis). De préférence, l’extrait aqueux est obtenu à partir d’une infusion de feuilles de thé, de préférence de feuilles de thé noir. De préférence, l’extrait
aqueux de feuilles de thé peut être une infusion de thé noir préparée avec 2 g/l à 50 g/l de feuilles de thé, plus préférentiellement avec 5 g/l à 10 g/l de feuilles de thé. According to a particular embodiment, the solution may also comprise an aqueous extract of tea leaves (Camellia sinensis). Preferably, the aqueous extract is obtained from an infusion of tea leaves, preferably black tea leaves. Preferably, the extract aqueous tea leaves may be a black tea infusion prepared with 2 g/l to 50 g/l of tea leaves, more preferably with 5 g/l to 10 g/l of tea leaves.
Le thé est préparé par l’ajout de feuilles sèches infusées dans de l'eau à une température de 70° C à 90° C durant 10 à 60 min. De préférence, on utilise 5 g/l à 10 g/l de feuilles de thé infusées 15 mn à 80° C. L'infusion peut être utilisée en l'état avec les feuilles, ou de manière plus commode la phase aqueuse est filtrée. The tea is prepared by adding dry leaves infused in water at a temperature of 70° C to 90° C for 10 to 60 min. Preferably, 5 g/l to 10 g/l of tea leaves are infused for 15 min at 80° C. The infusion can be used as is with the leaves, or more conveniently the aqueous phase is filtered. .
Les micro-organismes peuvent être introduits dans le milieu nutritif sous forme sèche et/ou humide ; le taux d'inoculation peut notamment être compris entre 103 CFU/g et 105 CFU/g de solution. La suspension microbienne peut ensuite être incubée entre 12°C et 45° C, de préférence entre 25° C et 35° C, plus préférentiellement à 25° C, 26° C, 27° C, 28° C, 29° C, 30°C, 31 °C, 32°C, 33°C, 34°C, ou 35°C encore plus préférentiellement à 26°C. Selon un mode particulièrement avantageux, l’incubation a lieu dans un réacteur ouvert, sans avoir besoin d’assurer des conditions aseptiques. The microorganisms can be introduced into the nutrient medium in dry and/or wet form; the inoculation rate may in particular be between 10 3 CFU/g and 10 5 CFU/g of solution. The microbial suspension can then be incubated between 12°C and 45°C, preferably between 25°C and 35°C, more preferably at 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, or 35°C even more preferably at 26°C. According to a particularly advantageous mode, the incubation takes place in an open reactor, without the need to ensure aseptic conditions.
La suspension peut être incubée pendant 1 à 21 , de préférence pendant 1 à 10 jours, plus préférentiellement pendant 3 à 4 jours, encore plus préférentiellement pendant 3 jours ou 4 jours. À la fin de la durée d’incubation, la flore totale dans la suspension peut être comprise entre 104 et 107 CFU/g. The suspension can be incubated for 1 to 21 days, preferably for 1 to 10 days, more preferably for 3 to 4 days, even more preferably for 3 days or 4 days. At the end of the incubation period, the total flora in the suspension may be between 10 4 and 10 7 CFU/g.
Le consortium ainsi obtenu est apte à réagir avec un substrat naturel, tel que des graines de Longoza, en milieu aqueux. Avantageusement, il est capable de diriger la fermentation extractive des graines de Longoza, pour rendre accessible, et éventuellement transformer, une grande diversité des composés qu'il renferme. The consortium thus obtained is capable of reacting with a natural substrate, such as Longoza seeds, in an aqueous medium. Advantageously, it is capable of directing the extractive fermentation of Longoza seeds, to make accessible, and possibly transform, a great diversity of the compounds it contains.
Étape b) : préparation des graines de Longoza Step b): Preparation of Longoza seeds
Selon l’étape b), les graines de Longoza sont broyées jusqu'à obtenir une poudre fine. Les particules de cette poudre présentent avantageusement une taille moyenne comprise entre 0,01 et 1 mm, de préférence entre 100 pm et 1 mm, plus préférentiellement entre 250 et 500 pm, encore plus préférentiellement une taille moyenne de 500 pm. De préférence, les graines sont crues. De préférence, les graines sont séchées avant d’être broyées. According to step b), the Longoza seeds are ground until a fine powder is obtained. The particles of this powder advantageously have an average size of between 0.01 and 1 mm, preferably between 100 μm and 1 mm, more preferentially between 250 and 500 μm, even more preferentially an average size of 500 μm. Preferably, the seeds are raw. Preferably, the seeds are dried before being ground.
L’étape b) peut être effectuée indifféremment avant, en même temps ou après l’étape a). Step b) can be carried out either before, at the same time or after step a).
Étape c) : préparation d’un mélange de fermentation
Selon l’étape c) du procédé, la poudre de graines de Longoza obtenue à l’étape b) est ajoutée dans un milieu fermentaire, comprenant la culture des microorganismes obtenue selon l’étape a) ainsi qu’un glucide, afin d’obtenir un mélange de fermentation. Step c): preparation of a fermentation mixture According to step c) of the process, the Longoza seed powder obtained in step b) is added to a fermentation medium, comprising the culture of the microorganisms obtained according to step a) as well as a carbohydrate, in order to obtain a fermentation mixture.
De préférence, la culture de micro-organismes est ajoutée dans le milieu fermentaire à un taux compris entre 102 CFU/g et 104 CFU/g de milieu fermentaire. De préférence, la culture de micro-organismes est ajoutée au milieu fermentaire à une concentration comprise entre 0,5 % et 15 % en poids rapporté au poids de milieu fermentaire, de préférence entre 0,75 et 10 %, plus préférentiellement à 5 %. Preferably, the culture of microorganisms is added to the fermentation medium at a rate of between 10 2 CFU/g and 10 4 CFU/g of fermentation medium. Preferably, the culture of microorganisms is added to the fermentation medium at a concentration of between 0.5% and 15% by weight based on the weight of fermentation medium, preferably between 0.75 and 10%, more preferably at 5% .
De préférence, les graines de Longoza en forme de poudre sont ajoutées au milieu fermentaire à une concentration comprise entre 1 et 75 g de graines par litre de milieu fermentaire (g/L), de préférence compris entre 10 et 60 g/L, plus préférentiellement compris entre 12 et 50 g/L, encore plus préférentiellement 12 g/L ou 50 g/L. Autrement dit, les graines de Longoza en forme de poudre sont ajoutées au milieu fermentaire à une concentration comprise entre 0,1 et 7,5 %, de préférence compris entre 1 et 6 %, plus préférentiellement compris entre 1 ,2 et 5 %, encore plus préférentiellement à une concentration de 1 ,2 ou 5 % en poids par rapport au volume total du milieu fermentaire. Preferably, the Longoza seeds in powder form are added to the fermentation medium at a concentration of between 1 and 75 g of seeds per liter of fermentation medium (g/L), preferably between 10 and 60 g/L, plus preferably between 12 and 50 g/L, even more preferably 12 g/L or 50 g/L. In other words, the Longoza seeds in powder form are added to the fermentation medium at a concentration of between 0.1 and 7.5%, preferably between 1 and 6%, more preferably between 1.2 and 5%, even more preferably at a concentration of 1, 2 or 5% by weight relative to the total volume of the fermentation medium.
Le milieu fermentaire comprend également un glucide, de préférence choisi parmi le saccharose, le glucose, le fructose, la mélasse ou un mélange d’un ou plusieurs de ceux-ci. The fermentation medium also comprises a carbohydrate, preferably chosen from sucrose, glucose, fructose, molasses or a mixture of one or more of these.
Selon un mode particulier, la solution peut comprendre un extrait aqueux de feuilles de thé, comme décrit ci-dessus. De préférence, l’extrait aqueux est obtenu à partir d’une infusion de feuilles de thé, de préférence de feuilles de thé noir. According to a particular mode, the solution can comprise an aqueous extract of tea leaves, as described above. Preferably, the aqueous extract is obtained from an infusion of tea leaves, preferably black tea leaves.
Afin de faciliter la dissolution du glucide dans le milieu fermentaire, ce dernier peut être chauffé avant ou après ajout du glucide, par exemple à une température compris entre 25°C et 90° C, préférentiellement 35° C. De préférence, en cas de chauffage du milieu fermentaire, ceci est fait avant ajout de la culture de micro-organismes ou alors à une température inférieure ou égale à 45° C, de préférence inférieure ou égale à 35° C, si après ajout de la culture. In order to facilitate the dissolution of the carbohydrate in the fermentation medium, the latter can be heated before or after addition of the carbohydrate, for example at a temperature between 25° C. and 90° C., preferably 35° C. Preferably, in the event of heating of the fermentation medium, this is done before adding the culture of microorganisms or else at a temperature less than or equal to 45° C., preferably less than or equal to 35° C., if after adding the culture.
Étape d) : incubation
Selon la prochaine étape d) du procédé, le mélange de fermentation obtenu à l’étape c) est ensuite incubé afin d’assurer la fermentation des graines de Longoza. Step d): incubation According to the next step d) of the method, the fermentation mixture obtained in step c) is then incubated in order to ensure the fermentation of the Longoza seeds.
L’incubation a lieu à une température comprise entre 12°C et 45° C, de préférence entre 25°C et 35°C, plus préférentiellement à 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31 °C, 32°C, 33°C, 34°C, ou 35°C, encore plus préférentiellement à 26°C. L’incubation est effectuée pendant une durée de 2 à 20 jours, de préférence pendant 7 à 13 jours, plus préférentiellement pendant 7, 8, 9, 10, 11 , 12, ou 13 jours, encore plus préférentiellement 10 jours. The incubation takes place at a temperature between 12°C and 45°C, preferably between 25°C and 35°C, more preferably at 25°C, 26°C, 27°C, 28°C, 29°C. C, 30°C, 31°C, 32°C, 33°C, 34°C, or 35°C, even more preferably at 26°C. The incubation is carried out for a period of 2 to 20 days, preferably for 7 to 13 days, more preferably for 7, 8, 9, 10, 11, 12, or 13 days, even more preferably 10 days.
Selon un aspect particulier, l’incubation a lieu dans un réacteur ouvert, sans avoir besoin d’assurer des conditions aseptiques. Selon un aspect particulier, l’incubation a lieu à un taux d’humidité compris entre 20 % à 60 %, de préférence entre 30 % à 50 %, plus préférentiellement de 40 %. According to a particular aspect, the incubation takes place in an open reactor, without the need to ensure aseptic conditions. According to a particular aspect, the incubation takes place at a humidity level of between 20% to 60%, preferably between 30% to 50%, more preferably 40%.
Étape e) : filtration Step e): filtration
Le mélange de fermentation est ensuite filtré lors de l’étape e). Par « filtration » on entend ici une étape permettant de séparer les fractions solides et liquides. La fraction solide peut notamment comprendre les graines de Longoza restantes et/ou des micro-organismes. Avantageusement, la filtration permet de retirer l’ensemble des micro-organismes présents dans le mélange, afin d’obtenir un extrait fermenté de graines de Longoza stérile. La filtration peut être réalisée par l’utilisation d’un ou plusieurs tamis et/ou filtres. Aussi, selon un mode de réalisation, l’étape e) correspond à une ou plusieurs étapes de filtration, de préférence comprenant au moins une étape de tamisage et/ou au moins une étape de filtration stérilisante. De préférence, l’étape e) comprend une étape de tamisage et une étape de filtration stérilisante. De préférence, la filtration stérilisante s’effectue sur un filtre ayant une taille moyenne de pores compris entre 0,1 pm à 0,2 pm, de préférence de 0,2 pm. De façon avantageuse, le tamisage permet de retirer le débris de poudre. De façon avantageuse, une filtration stérilisante permet de retirer tout débris cellulaire de manière rapide et peu coûteuse. De préférence, au moins un des filtres est un filtre de cellulose. The fermentation mixture is then filtered during step e). By “filtration” is meant here a step making it possible to separate the solid and liquid fractions. The solid fraction may in particular comprise the remaining Longoza seeds and/or microorganisms. Advantageously, filtration makes it possible to remove all the microorganisms present in the mixture, in order to obtain a fermented extract of sterile Longoza seeds. Filtration can be achieved by using one or more sieves and/or filters. Also, according to one embodiment, step e) corresponds to one or more filtration steps, preferably comprising at least one sieving step and/or at least one sterilizing filtration step. Preferably, step e) comprises a sieving step and a sterilizing filtration step. Preferably, the sterilizing filtration is carried out on a filter having an average pore size of between 0.1 μm and 0.2 μm, preferably 0.2 μm. Advantageously, the sieving makes it possible to remove the powder debris. Advantageously, sterilizing filtration makes it possible to remove any cellular debris quickly and inexpensively. Preferably, at least one of the filters is a cellulose filter.
Étape f) : concentration et/ou formulation (optionnelle) Step f): concentration and/or formulation (optional)
Le procédé décrit ci-dessus permet d’obtenir un extrait fermenté de graines de Longoza clarifié. Toutefois, dans certains cas, il peut être avantageux d’effectuer une ou plusieurs étapes supplémentaires, par exemple de concentration ou de formulation. Le procédé selon
l'invention peut ainsi en outre comprendre au moins une étape supplémentaire et postérieure à l’étape e) de concentration ou de formulation. The process described above makes it possible to obtain a fermented extract of clarified Longoza seeds. However, in certain cases, it may be advantageous to carry out one or more additional steps, for example concentration or formulation. The process according to the invention can thus also comprise at least one additional step and subsequent to step e) of concentration or formulation.
Dans un mode de réalisation particulier, le procédé selon l'invention comprend en outre, après l'étape f) de filtration, une ou plusieurs des étapes suivantes visant notamment à adapter la composition à une formulation particulière : In a particular embodiment, the method according to the invention further comprises, after step f) of filtration, one or more of the following steps aimed in particular at adapting the composition to a particular formulation:
- une étape de concentration ; et/ou - a concentration step; and or
- une étape de formulation. - a formulation step.
Chaque étape optionnelle identifiée ci-dessus peut être présente en tant qu ’étape supplémentaire unique du procédé, ou en combinaison avec une ou plusieurs autres étapes optionnelles. De préférence, le procédé fermentation comprend une étape f) d’ajout d’au moins un conservateur à l’extrait fermenté de graines de Longoza. De préférence, ledit conservateur est choisi parmi le butylène glycol, la glycérine, le propylène glycol, le benzoate de sodium benzoate et le sorbate de potassium, plus préférentiellement la glycérine. Dans certains cas, au moins deux conservateurs peuvent être ajoutés à l’extrait fermenté de graines de Longoza. De préférence, le conservateur est ajouté à l’extrait fermenté de graines de Longoza de l’étape f) à une concentration finale compris entre 50 et 80 %, de préférence compris entre 65 et 75 %, plus préférentiellement 70 %, en poids par rapport au poids total de l’extrait sous la forme d’une solution. Lorsque le conservateur est ajouté à l’extrait fermenté de graines de Longoza de l’étape e) à une concentration finale compris entre 50 et 80 %, ledit conservateur est sélectionné parmi le butylène glycol, la glycérine et le propylène glycol. Each optional step identified above may be present as a single additional process step, or in combination with one or more other optional steps. Preferably, the fermentation process comprises a step f) of adding at least one preservative to the fermented extract of Longoza seeds. Preferably, said preservative is chosen from butylene glycol, glycerin, propylene glycol, sodium benzoate benzoate and potassium sorbate, more preferentially glycerin. In some cases, two or more preservatives may be added to the fermented Longoza seed extract. Preferably, the preservative is added to the fermented Longoza seed extract of step f) at a final concentration of between 50 and 80%, preferably between 65 and 75%, more preferably 70%, by weight per relative to the total weight of the extract in the form of a solution. When the preservative is added to the fermented extract of Longoza seeds from step e) at a final concentration of between 50 and 80%, said preservative is selected from butylene glycol, glycerin and propylene glycol.
L’extrait fermenté de graines de Longoza est préférablement conservé à environ 4°C (4 ± 2°C) et/ou à l'obscurité à l’issue de l’étape e) de filtration ou à l’issue de toute autre étape lorsqu’une étape supplémentaire est présente après l’étape e). Lorsque le procédé comprend l’ajout d’au moins un conservateur, l’extrait fermenté de graines de Longoza est préférablement conservé à température ambiante. The fermented extract of Longoza seeds is preferably stored at around 4°C (4 ± 2°C) and/or in the dark at the end of step e) of filtration or at the end of any other step when an additional step is present after step e). When the method includes the addition of at least one preservative, the fermented extract of Longoza seeds is preferably stored at room temperature.
L’extrait fermenté de graines de Longoza est référencé sous la nomenclature internationale, INCI : « Water, glycerin, Aframomum angustifolium seed extract, lactobacillus ferment lysate, yeast ferment extract ». Ce produit contient notamment 1 ,2 à 1 ,65 % en poids d’extrait sec d’extrait fermenté de graines de Longoza dans un mélange eau/glycérine.
Composition cosmétique The fermented extract of Longoza seeds is referenced under the international nomenclature, INCI: “Water, glycerin, Aframomum angustifolium seed extract, lactobacillus ferment lysate, yeast ferment extract”. This product contains in particular 1.2 to 1.65% by weight of dry extract of fermented extract of Longoza seeds in a water/glycerin mixture. Cosmetic composition
De façon surprenante, les inventeurs ont mis en évidence que l’extrait fermenté de graines de Longoza présente in vitro des effets bénéfiques sur la peau, permettant notamment d’augmenter le nombre et/ou la densité des fibroblastes, ainsi que l’expression de diverses protéines impliquées dans la solidité mécanique de la peau, son renouvellement et son élasticité, telles que l’élafine, la desmogléine 1 et la loricrine. Ainsi, l’extrait fermenté de graines de Longoza permet de lutter contre les signes du vieillissement cutané liés à l’âge et/ou aux stress, notamment la perte de fermeté et/ou d’élasticité et l’altération de la fonction barrière de la peau. Surprisingly, the inventors have demonstrated that the fermented extract of Longoza seeds has beneficial effects on the skin in vitro, making it possible in particular to increase the number and/or density of fibroblasts, as well as the expression of various proteins involved in the mechanical strength of the skin, its renewal and its elasticity, such as elafin, desmoglein 1 and loricrin. Thus, the fermented extract of Longoza seeds makes it possible to fight against the signs of skin aging linked to age and/or stress, in particular the loss of firmness and/or elasticity and the alteration of the barrier function of the skin.
Selon l’invention, l’extrait fermenté de graines de Longoza est utilisé dans une quantité efficace pour obtenir l’effet recherché. Il peut être utilisé tel quel ou avantageusement incorporé dans une composition cosmétique adaptée à une application topique sur les matières kératiniques. According to the invention, the fermented extract of Longoza seeds is used in an effective amount to obtain the desired effect. It can be used as it is or advantageously incorporated into a cosmetic composition suitable for topical application to keratin materials.
En particulier, l’extrait fermenté de graines de Longoza est utilisé tel quel ou est présent dans une composition cosmétique. In particular, the fermented extract of Longoza seeds is used as such or is present in a cosmetic composition.
Aussi, un autre objet de l’invention porte sur une composition cosmétique comprenant, dans un milieu physiologiquement acceptable, un extrait fermenté de graines de Longoza selon l’invention. Also, another object of the invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, a fermented extract of Longoza seeds according to the invention.
Par « composition cosmétique » on entend toute composition à visée cosmétique, c’est à dire esthétique, pouvant être mise en contact avec les parties superficielles du corps humain et plus particulièrement avec les matières kératiniques, en particulier la peau et/ou les lèvres humaines. By “cosmetic composition” is meant any composition for cosmetic purposes, that is to say aesthetic, which can be brought into contact with the superficial parts of the human body and more particularly with keratin materials, in particular the skin and / or the human lips. .
Par « milieu physiologiquement acceptable » on entend tout excipient convenant à une utilisation topique, en contact avec les matières kératiniques, sans risque de toxicité, d'incompatibilité, d'instabilité et/ou de réponse allergique. By “physiologically acceptable medium” is meant any excipient suitable for topical use, in contact with keratin materials, without risk of toxicity, incompatibility, instability and/or allergic response.
Par « matières kératiniques » selon l’invention, on entend la peau et/ou ses phanères, et plus particulièrement la peau et/ou les lèvres humaines. En particulier, il s’agira de la peau du visage et/ou du cou et/ou du corps, et des lèvres.
Les matières kératiniques selon l’invention sont notamment des matières kératiniques saines (sujets « sains »), c’est-à-dire ne présentant pas de troubles ou de désordres qui relèveraient d’un état pathologique (sujets « non sains », atteints d’une pathologie). On parlera indifféremment de peaux et/ou lèvres saines ou de peaux et/ou lèvres dans le reste de la description. By “keratin materials” according to the invention, is meant the skin and/or its appendages, and more particularly the human skin and/or lips. In particular, it will be the skin of the face and/or of the neck and/or of the body, and of the lips. The keratin materials according to the invention are in particular healthy keratin materials (“healthy” subjects), that is to say not exhibiting disorders or disorders which would be part of a pathological state (“non-healthy” subjects, affected of a pathology). Reference will be made indiscriminately to healthy skin and/or lips or to healthy skin and/or lips in the rest of the description.
L’extrait fermenté de graines de Longoza est présent dans la composition de l’invention en une teneur allant de 0,0001 % à 5 %, de préférence de 0,0005 % à 2 %, plus préférentiellement de 0,001 % à 1 % en poids de matière première (solution d’extrait fermenté obtenue selon le procédé décrit ci-dessus) par rapport au poids total de la composition. Ainsi l’extrait fermenté de graines de Longoza est présent dans la composition de l’invention en une teneur allant de 0,0000012 % à 0,0825 %, de préférence de 0,000006 % à 0,033 %, plus préférentiellement de 0,000012 % à 0,0165 % en poids de matière active (extrait fermenté de graines de Longoza) par rapport au poids total de la composition. The fermented extract of Longoza seeds is present in the composition of the invention in a content ranging from 0.0001% to 5%, preferably from 0.0005% to 2%, more preferably from 0.001% to 1% by weight of raw material (solution of fermented extract obtained according to the method described above) relative to the total weight of the composition. Thus the fermented extract of Longoza seeds is present in the composition of the invention in a content ranging from 0.0000012% to 0.0825%, preferably from 0.000006% to 0.033%, more preferably from 0.000012 % to 0.0165% by weight of active ingredient (fermented extract of Longoza seeds) relative to the total weight of the composition.
Les ingrédients additionnels utilisés avantageusement dans la composition de l’invention peuvent être présents en une teneur allant de 0,0001% à 10%, de préférence de 0,001% à 5% en poids (de matière première) par rapport au poids total de la composition. The additional ingredients advantageously used in the composition of the invention may be present in a content ranging from 0.0001% to 10%, preferably from 0.001% to 5% by weight (of raw material) relative to the total weight of the composition.
Le milieu physiologiquement acceptable représente généralement de 1 à 99% en poids, par rapport au poids total de ladite composition. Le milieu physiologiquement acceptable de la composition selon l'invention comprend de l'eau et éventuellement le conservateur tel que défini précédemment. The physiologically acceptable medium generally represents from 1 to 99% by weight, relative to the total weight of said composition. The physiologically acceptable medium of the composition according to the invention comprises water and optionally the preservative as defined above.
Dans un mode de réalisation particulier, ladite composition cosmétique comprenant un extrait fermenté de graines de Longoza selon l’invention est une composition de soin et/ou de maquillage des matières kératiniques, en particulier de la peau et/ou des lèvres et notamment de la peau du visage et/ou du cou. In a particular embodiment, said cosmetic composition comprising a fermented extract of Longoza seeds according to the invention is a composition for caring for and/or making up keratin materials, in particular the skin and/or the lips and in particular the face and/or neck skin.
La composition cosmétique de l’invention comprend généralement, outre l’extrait fermenté de graines de Longoza et le milieu physiologiquement acceptable, un ou plusieurs excipients cosmétiques acceptables parmi ceux connus de l’homme du métier en vue d’obtenir une composition pour l’application topique par exemple sous forme de lait, de crème, de pommade, d’émulsion eau-dans-huile ou huile-dans-eau, de baume, de stick, de gel, de lotion, de sérum, ou encore de poudre.
La composition cosmétique de l’invention peut également se présenter sous forme d’un patch ou d’un masque, notamment un masque sous forme d’une crème épaisse, ou encore sous forme d’un masque cellulosique imbibé d’extrait fermenté de graines de Longoza ou d’une composition en contenant. The cosmetic composition of the invention generally comprises, in addition to the fermented extract of Longoza seeds and the physiologically acceptable medium, one or more cosmetic excipients acceptable from those known to those skilled in the art with a view to obtaining a composition for the topical application, for example in the form of a milk, a cream, an ointment, a water-in-oil or oil-in-water emulsion, a balm, a stick, a gel, a lotion, a serum, or even a powder. The cosmetic composition of the invention may also be in the form of a patch or a mask, in particular a mask in the form of a thick cream, or else in the form of a cellulose mask soaked in fermented extract of seeds of Longoza or a composition containing it.
Dans un mode de réalisation préféré, ladite composition est sous la forme d’une crème, émulsion, solution, suspension, gel, lait, lotion, ou sérum. Lorsque la composition est sous la forme d’une émulsion, l’émulsion peut être une émulsion huile-dans-eau, ou eau-dans- huile ou émulsion multiple. In a preferred embodiment, said composition is in the form of a cream, emulsion, solution, suspension, gel, milk, lotion, or serum. When the composition is in the form of an emulsion, the emulsion may be an oil-in-water or water-in-oil emulsion or multiple emulsion.
La composition cosmétique de l’invention peut se présenter sous toute forme galénique adaptée à une application topique sur les matières kératiniques en particulier de la peau et/ou des lèvres et notamment de la peau du visage et/ou du cou comprenant l’extrait fermenté de graines de Longoza et au moins un ingrédient cosmétique choisi parmi les antioxydants, les parfums, les vitamines, les agents épaississants, les agents émollients, les agents hydratants, les agents anti-âge, les agents liftants, les agents tenseurs, les agents repulpants, les agents apaisants, les agents antipollution, les agents éclaircissants ou dépigmentants, les charges, les nacres et leurs mélanges. The cosmetic composition of the invention may be in any galenic form suitable for topical application to keratin materials, in particular of the skin and/or of the lips and in particular of the skin of the face and/or of the neck comprising the fermented extract of Longoza seeds and at least one cosmetic ingredient chosen from antioxidants, perfumes, vitamins, thickening agents, emollient agents, moisturizing agents, anti-aging agents, lifting agents, tensing agents, plumping agents , soothing agents, antipollution agents, lightening or depigmenting agents, fillers, nacres and mixtures thereof.
Aussi, selon un objet préféré de l’invention, la composition cosmétique peut comprendre en outre au moins un adjuvant cosmétique choisi dans le groupe constitué par des agents antioxydants, des agents émollients, des agents hydratants, des agents anti-âge, et leurs mélanges. Also, according to a preferred subject of the invention, the cosmetic composition may also comprise at least one cosmetic adjuvant chosen from the group consisting of antioxidants, emollients, moisturizing agents, anti-aging agents, and mixtures thereof. .
Selon la nature de la composition, on sélectionnera un ou plusieurs excipients cosmétiquement acceptables parmi des émulsionnants, des polymères, des agents tensioactifs, des agents de rhéologie, des électrolytes, des ajusteurs de pH, des agents antioxydants, des conservateurs, des colorants, et leurs mélanges. Depending on the nature of the composition, one or more cosmetically acceptable excipients will be selected from emulsifiers, polymers, surfactants, rheology agents, electrolytes, pH adjusters, antioxidants, preservatives, colorants, and their mixtures.
À titre d’exemple particulier, la composition cosmétique peut comprendre des gélifiants hydrophiles, des antioxydants, des conservateurs et leurs mélanges. By way of specific example, the cosmetic composition may comprise hydrophilic gelling agents, antioxidants, preservatives and mixtures thereof.
Procédé cosmétique
La présente invention a également pour objet un procédé cosmétique de soin et/ou de maquillage des matières kératiniques, en particulier de la peau et/ou des lèvres et notamment de la peau du visage et/ou du cou, comprenant l’application topique sur lesdites matières kératiniques, d’au moins une couche de l’extrait fermenté de graines de Longoza ou d’une composition cosmétique en contenant telle que décrite selon l’invention. Cosmetic process The present invention also relates to a cosmetic process for caring for and/or making up keratin materials, in particular the skin and/or the lips and in particular the skin of the face and/or the neck, comprising the topical application on said keratin materials, of at least one layer of the fermented extract of Longoza seeds or of a cosmetic composition containing it as described according to the invention.
Le procédé cosmétique de la présente invention est notamment destiné à favoriser et/ou stimuler le renouvellement-épidermique, la desquamation de la peau, la vitalité des cellules cutanées, et/ou la cohésion des cellules cutanées, et/ou prévenir et/ou diminuer les signes du vieillissement cutané, notamment la perte de fermeté, la perte d’élasticité, la perte de densité, l’apparition de rides et/ou ridules, la sécheresse de la peau, l’altération de la fonction barrière de la peau, l’altération de la souplesse de la peau et/ou l’altération de l’homogénéité ou de l’éclat du teint. The cosmetic process of the present invention is in particular intended to promote and/or stimulate epidermal renewal, desquamation of the skin, the vitality of the skin cells, and/or the cohesion of the skin cells, and/or prevent and/or reduce the signs of skin aging, in particular loss of firmness, loss of elasticity, loss of density, appearance of wrinkles and/or fine lines, dryness of the skin, alteration of the barrier function of the skin, the alteration of the suppleness of the skin and/or the alteration of the homogeneity or the radiance of the complexion.
Par « favoriser et/ou stimuler le renouvellement épidermique » on entend que l’extrait fermenté de graines de Longoza est destiné à promouvoir la différenciation kératinocytaire. By “promoting and/or stimulating epidermal renewal” is meant that the fermented extract of Longoza seeds is intended to promote keratinocyte differentiation.
Par « favoriser et/ou stimuler la desquamation de la peau », on entend notamment que l’extrait fermenté de graines de Longoza est destiné à promouvoir le renouvellement et le développement cellulaire et tissulaire cutané, notamment de la peau et/ou des lèvres. By "promoting and/or stimulating the desquamation of the skin", we mean in particular that the fermented extract of Longoza seeds is intended to promote the renewal and development of cutaneous cells and tissues, in particular of the skin and/or the lips.
Par « favoriser et/ou stimuler la vitalité des cellule cutanées », on entend notamment que l’extrait fermenté de graines de Longoza est destiné à promouvoir l’état général de la peau, son éclat. By “promoting and/or stimulating the vitality of skin cells”, we mean in particular that the fermented extract of Longoza seeds is intended to promote the general condition of the skin, its radiance.
Par « prévenir et/ou diminuer les signes du vieillissement cutané » on entend notamment que l’extrait fermenté de graines de Longoza est destiné à diminuer et/ou retarder la perte de fermeté, la perte d’élasticité, la perte de densité, la sécheresse de la peau, la perte de souplesse, et/ou l’apparition de rides et/ou ridules. By “preventing and/or reducing the signs of skin ageing” is meant in particular that the fermented extract of Longoza seeds is intended to reduce and/or delay the loss of firmness, the loss of elasticity, the loss of density, the dryness of the skin, loss of suppleness, and/or the appearance of wrinkles and/or fine lines.
Par « prévenir et/ou diminuer l’altération de l’homogénéité ou de l’éclat du teint » on entend notamment que l’extrait fermenté de graines de Longoza est destiné à diminuer et/ou retarder l’apparition des imperfections ou microreliefs de la peau, des cernes, d’un teint brouillé, terne et/ou non uniforme.
Par « prévenir et/ou diminuer l’altération de la fonction barrière de la peau » on entend notamment que l’extrait fermenté de graines de Longoza est destiné à diminuer et/ou retarder des modifications de l’intégrité de la peau, qui peuvent être associés, par exemple, à des modifications des interactions entre les cellules et/ou entre des cellules et la matrice extracellulaire, susceptibles de générer une altération des différentes fonctions de la barrière cutanée (ex : mécanique, hydrique, antioxydante...). By "preventing and/or reducing the alteration of the homogeneity or radiance of the complexion" is meant in particular that the fermented extract of Longoza seeds is intended to reduce and/or delay the appearance of imperfections or microreliefs of the skin, dark circles, a hazy, dull and/or uneven complexion. By "preventing and/or reducing the alteration of the barrier function of the skin" is meant in particular that the fermented extract of Longoza seeds is intended to reduce and/or delay changes in the integrity of the skin, which can be associated, for example, with modifications of the interactions between cells and/or between cells and the extracellular matrix, likely to generate an alteration of the various functions of the skin barrier (eg: mechanical, water, antioxidant, etc.).
Selon un mode particulier, ledit extrait fermenté de graines de Longoza selon l’invention ou ladite composition cosmétique en contenant est appliqué sur une peau âgée ou présentant des signes de vieillissement et/ou une peau exposée à un stress, de préférence une peau âgée ou présentant des signes de vieillissement. According to a particular embodiment, said fermented extract of Longoza seeds according to the invention or said cosmetic composition containing it is applied to aged skin or showing signs of aging and/or skin exposed to stress, preferably aged skin or showing signs of aging.
Par « peau exposée à un stress », on entend que la peau est soumise à un stress d’origine endogène ou exogène, notamment un stress mécanique ou chimique susceptible d’induire des réactions cutanées non pathologiques inesthétiques - par ex. la peau est visiblement fatiguée et/ou plus sensible aux stimuli. By "skin exposed to stress", we mean that the skin is subjected to stress of endogenous or exogenous origin, in particular mechanical or chemical stress likely to induce unsightly non-pathological skin reactions - e.g. the skin is visibly tired and/or more sensitive to stimuli.
Les peaux et lèvres sur lesquelles sont appliquées les compositions de l’invention, sont saines, c’est-à-dire ne présentant pas de troubles ou de désordres qui relèveraient d’un état pathologique (sujets « non sains », atteints d’une pathologie). The skins and lips to which the compositions of the invention are applied are healthy, that is to say not showing any disorders or disorders that would come under a pathological condition (“non-healthy” subjects, suffering from pathology).
De façon avantageuse, les compositions comprenant de l’extrait fermenté de graines de Longoza employées dans le cadre du procédé cosmétique de l’invention sont celles décrites ci-dessus. Advantageously, the compositions comprising the fermented extract of Longoza seeds used in the context of the cosmetic process of the invention are those described above.
Utilisation de l’extrait fermenté de graines de Longoza Use of Fermented Longoza Seed Extract
Un autre objet de l’invention porte sur l’utilisation cosmétique de l’extrait fermenté de graines de Longoza selon l’invention pour une application topique sur les matières kératiniques, en particulier la peau et/ou les lèvres et notamment de la peau du visage et/ou du cou, en tant qu’actif cosmétique destiné à favoriser et/ou stimuler le renouvellement épidermique, la desquamation de la peau, la vitalité des cellules cutanées, et/ou la cohésion des cellules cutanées, et/ou prévenir et/ou diminuer les signes du vieillissement cutané, notamment la perte de fermeté, la perte d’élasticité, la perte de densité, l’apparition de rides et/ou ridules, la sécheresse de la peau, l’altération de la
fonction barrière de la peau, l’altération de la souplesse de la peau et/ou l’altération de l’homogénéité ou de l’éclat du teint. Another object of the invention relates to the cosmetic use of the fermented extract of Longoza seeds according to the invention for topical application to keratin materials, in particular the skin and/or the lips and in particular the skin of the face and/or neck, as a cosmetic active ingredient intended to promote and/or stimulate epidermal renewal, desquamation of the skin, the vitality of the skin cells, and/or the cohesion of the skin cells, and/or to prevent and /or reduce the signs of skin aging, in particular loss of firmness, loss of elasticity, loss of density, appearance of wrinkles and/or fine lines, dryness of the skin, alteration of the barrier function of the skin, the alteration of the suppleness of the skin and/or the alteration of the homogeneity or the radiance of the complexion.
Exemples Examples
L'invention est illustrée par les exemples non limitatifs suivants. Les % sont exprimés en poids de matière première par rapport au poids total de la composition, sauf indication contraire. The invention is illustrated by the following non-limiting examples. The % are expressed by weight of raw material relative to the total weight of the composition, unless otherwise indicated.
Exemple 1 : Procédé de fermentation de graines de Longoza Example 1: Process for Fermenting Longoza Seeds
Matériel et méthodes Material and methods
Consortium de micro-organismes Consortium of microorganisms
Les micro-organismes faisant partie du consortium comprennent : The microorganisms that are part of the consortium include:
- au moins une bactérie lactique appartenant au genre Lactobacillus ou Pediococcus,- at least one lactic acid bacterium belonging to the genus Lactobacillus or Pediococcus,
- au moins une levure appartenant au genre Saccharomyces, Schyzosaccharomyces ou Torulaspora, et - at least one yeast belonging to the genus Saccharomyces, Schyzosaccharomyces or Torulaspora, and
- au moins une bactérie acétique appartenant au genre Acetobacter, Gluconobacter ou Komagataeibacter. - at least one acetic bacterium belonging to the genus Acetobacter, Gluconobacter or Komagataeibacter.
Préparation des graines de Longoza Preparation of Longoza seeds
Des graines crues de Longoza sont broyées afin d’obtenir une poudre composée de particules ayant une taille moyenne d’environ 250 à 500pm. Raw Longoza seeds are crushed to obtain a powder composed of particles having an average size of about 250 to 500 pm.
Préparation du milieu nutritif Preparation of the nutrient medium
Le thé est préparé à partir de 5 g/l à 10 g/l de feuilles de thé infusées durant 10 à 60 min à 70° C à 90° C. Le saccharose est ensuite dissous dans la phase aqueuse à une concentration, comprise entre 20 g/l et 100 g/l, en général de 50 g/l. Le saccharose peut notamment être remplacé par un mélange de glucose et fructose. The tea is prepared from 5 g/l to 10 g/l of tea leaves infused for 10 to 60 min at 70°C to 90°C. The sucrose is then dissolved in the aqueous phase at a concentration between 20 g/l and 100 g/l, generally 50 g/l. Sucrose can in particular be replaced by a mixture of glucose and fructose.
Procédé de fermentation Fermentation process
Une fermentation de graines de Longoza a été effectuée selon un procédé comprenant les étapes suivantes : a) l’incubation d’un consortium de micro-organismes dans une solution comprenant un glucide et un extrait aqueux de feuilles de thé noir (autrement dit le « milieu nutritif ») à 26°C pendant 3 à 4 jours afin d’obtenir une culture ; b) le broyage de graines de Longoza afin d’obtenir une poudre fine, comme décrit ci-
dessus ; c) l’ajout, dans un milieu fermentaire comprenant de l’eau déchloré et un glucide, de :Fermentation of Longoza seeds was carried out according to a process comprising the following steps: a) incubation of a consortium of microorganisms in a solution comprising a carbohydrate and an aqueous extract of black tea leaves (i.e. the " nutrient medium”) at 26°C for 3 to 4 days in order to obtain a culture; b) the grinding of Longoza seeds in order to obtain a fine powder, as described below above ; c) the addition, in a fermentation medium comprising dechlorinated water and a carbohydrate, of:
- la poudre de graines de Longoza à une concentration de 1 ,2 % ou 5 % en poids rapporté au litre de milieu fermentaire, et - Longoza seed powder at a concentration of 1.2% or 5% by weight based on the liter of fermentation medium, and
- la culture obtenue à l’étape a) à une concentration de 5 % en poids rapporté au poids de milieu fermentaire, afin d’obtenir un mélange de fermentation ; d) l’incubation du mélange de fermentation obtenu à l’étape c) dans un fermenteur à 26° C pendant 10 jours ; e) la filtration du mélange de fermentation par tamisage grossier suivi par une filtration sur un filtre de cellulose ayant une taille moyenne de pores de 0,2 pm afin d’obtenir un extrait fermenté de graines de Longoza, et, f) ajout de la glycérine à l’extrait fermenté de graines de Longoza à une concentration finale de 70 % en poids par rapport au poids total. - the culture obtained in step a) at a concentration of 5% by weight relative to the weight of fermentation medium, in order to obtain a fermentation mixture; d) incubation of the fermentation mixture obtained in step c) in a fermenter at 26° C. for 10 days; e) filtering the fermentation mixture by coarse sieving followed by filtration through a cellulose filter having an average pore size of 0.2 µm to obtain a fermented Longoza seed extract, and, f) adding the glycerin with fermented extract of Longoza seeds at a final concentration of 70% by weight relative to the total weight.
Résultats Results
On obtient un extrait fermenté de graines de Longoza sous la forme d’une solution à une concentration de 1 ,2 à 1 ,35 % en poids de matière active de graines de Longoza fermenté, 70 % de glycérine et 28,65 à 28,8 % d’eau. De façon alternative, on obtient un extrait fermenté de graines de Longoza sous la forme d’une solution à une concentration de 1 ,35 à 1 ,65 % en poids de matière active de graines de Longoza fermenté, 70 % de glycérine et 28,35 à 28,65 % d’eau. A fermented extract of Longoza seeds is obtained in the form of a solution at a concentration of 1.2 to 1.35% by weight of active ingredient of fermented Longoza seeds, 70% glycerin and 28.65 to 28, 8% water. Alternatively, a fermented extract of Longoza seeds is obtained in the form of a solution at a concentration of 1.35 to 1.65% by weight of active ingredient of fermented Longoza seeds, 70% glycerin and 28, 35 to 28.65% water.
L’extrait fermenté de graines de Longoza obtenu à partir d’une concentration de graines de Longoza de 1 ,2 % en poids rapporté au litre de milieu fermentaire (soit 12 g/L) à l’étape c) est nommé ci-après l’extrait « L3 ». The fermented extract of Longoza seeds obtained from a concentration of Longoza seeds of 1.2% by weight relative to the liter of fermentation medium (i.e. 12 g/L) in step c) is named below the “L3” extract.
L’extrait fermenté de graines de Longoza obtenu à partir d’une concentration de graines de Longoza de 5 % en poids rapporté au litre de milieu fermentaire (soit 50 g/L) à l’étape c) est nommé ci-après l’extrait « L2 ». The fermented extract of Longoza seeds obtained from a concentration of Longoza seeds of 5% by weight relative to the liter of fermentation medium (i.e. 50 g/L) in step c) is named below the extract “L2”.
L’effet de ces extraits va être illustré dans les exemples suivants. The effect of these extracts will be illustrated in the following examples.
Exemple 2 : Caractérisation d’un extrait fermenté de graines de Longoza Example 2: Characterization of a fermented extract of Longoza seeds
Matériel et méthodes
Quantification des acides organiques par analyse HPLC Material and methods Quantification of organic acids by HPLC analysis
Le dosage a été réaliser sur une HPLC-DÀD-MS 1260 agilent. The assay was carried out on an agilent HPLC-DÀD-MS 1260.
L’extrait est injecté à 0,02%, dilué au 1 /50ème dans HCOOH 0,1% (pesée de 20 pL qsp 1 mL) Les paramètres dans la méthode d’acquisition citée ci-dessus sont les suivants : The extract is injected at 0.02%, diluted to 1/ 50th in 0.1% HCOOH (weighing 20 pL qsp 1 mL) The parameters in the acquisition method cited above are as follows:
Volume d’injection : 5 L Température : 30° C Colonne : Phenomenex Hydro-RP 150x4.6mm 4pm (n°8) Solvants : Injection volume: 5 L Temperature: 30° C Column: Phenomenex Hydro-RP 150x4.6mm 4pm (n°8) Solvents:
Isocratique 100% À : H2O + 0,1% acide formique Isocratic 100% À: H2O + 0.1% formic acid
Débit : 0.400mL/min Flow rate: 0.400mL/min
Durée d’analyse 25 min Analysis time 25 min
RMN NMR
Chromatographie de partage centrifuge (CPC) Centrifugal partition chromatography (CPC)
L’extrait fermenté de graines de Longoza a été lyophilisé afin de réduire la quantité en eau. La masse injectée été d’environ 4 g. Longoza seed fermented extract has been freeze-dried to reduce the amount of water. The mass injected was about 4 g.
Après équilibrage de la colonne, l'extrait fermenté de graines de Longoza a été dissous dans 11 ml de phase inférieure + 6 ml de phase supérieure et injecté dans la colonne CPC (colonne de 303 mL, instrument FCPE300® (Rousselet Robatel Kromaton)) via une boucle d’échantillonnage de 20 ml. La phase mobile a été pompée en mode ascendant pendant 65 min. La colonne a été extrudée en commutant la vanne de sélection de mode pendant 10 minutes. Le taux de débit a été de 20 mL/min et la vitesse de rotation de la colonne de 1300 rpm. Le système de solvant à deux phases correspond à l’acétate d’éthyle/acétonitrile/eau (3/3/4, v/v). La phase stationnaire correspond à la phase inférieure du système de solvants à deux phases (mode ascendant) alors que la phase mobile correspond à phase supérieure du système de solvants à deux phases. After column equilibration, the fermented extract of Longoza seeds was dissolved in 11 ml lower phase + 6 ml upper phase and injected into the CPC column (303 mL column, FCPE300® instrument (Rousselet Robatel Kromaton)) via a 20 ml sample loop. The mobile phase was pumped upwards for 65 min. The column was extruded by switching the mode selector valve for 10 minutes. The flow rate was 20 mL/min and the column rotation speed was 1300 rpm. The two-phase solvent system is ethyl acetate/acetonitrile/water (3/3/4, v/v). The stationary phase corresponds to the lower phase of the two-phase solvent system (bottom-up mode) while the mobile phase corresponds to the upper phase of the two-phase solvent system.
Des fractions de 20 ml ont été collectées pendant toute l’expérience (élution et extrusion) et combinées selon leurs profils de chromatographie sur couche mince. 10 fractions ont ainsi été obtenues. 20 ml fractions were collected throughout the experiment (elution and extrusion) and combined according to their thin layer chromatography profiles. 10 fractions were thus obtained.
Identification des principaux métabolites
Un aliquot de chaque fraction de F1 à F10 a été dissoute dans 700 pL de DMSO-d6 et analysée par RMN 13C à 298 K sur un spectromètre Bruker Avance AVII I -600 (Karlsruhe, Allemagne) équipé d”une cryosonde. Après le traitement des spectres, les intensités absolues de tous les signaux RMN 13C ont été automatiquement collectées et regroupées sur les spectres des séries de fractions en utilisant un script informatique développé par Natexplore. Le tableau résultant a été soumis à une analyse de regroupement hiérarchique (PermutMatrix, 1.9.3, LIRAAM, Montpellier, France). Les grappes de déplacement chimique RMN 13C résultantes ont été visualisées sous forme de dendrogrammes sur une carte bidimensionnelle. Pour l'identification des métabolites, chaque grappe de décalage chimique RMN 13C obtenue par HCA a été manuellement soumise au moteur de recherche de structure du logiciel de gestion de base de données ACD/NMR Workbook Suite 2012 (ACD/Labs, Ontario, Canada) comprenant les structures et les décalages chimiques prévus des produits naturels de faible poids moléculaire. Des expériences de RMN 2D (HSQC, HMBC et COSY) ont été réalisées sur des fractions contenant des composés supposés identifiés afin de confirmer les structures moléculaires proposées par la base de données à la fin du processus de déréplication. Identification of major metabolites An aliquot of each fraction from F1 to F10 was dissolved in 700 μL of DMSO-d6 and analyzed by 13 C NMR at 298 K on a Bruker Avance AVII I-600 spectrometer (Karlsruhe, Germany) equipped with a cryoprobe. After the spectra were processed, the absolute intensities of all 13 C NMR signals were automatically collected and aggregated onto the fraction series spectra using a computer script developed by Natexplore. The resulting table was subjected to a hierarchical clustering analysis (PermutMatrix, 1.9.3, LIRAAM, Montpellier, France). The resulting 13C NMR chemical shift clusters were visualized as dendrograms on a two-dimensional map. For the identification of metabolites, each 13 C NMR chemical shift cluster obtained by HCA was manually submitted to the structure search engine of the ACD/NMR Workbook Suite 2012 database management software (ACD/Labs, Ontario, Canada ) understanding the predicted chemical structures and shifts of low molecular weight natural products. 2D NMR experiments (HSQC, HMBC and COZY) were carried out on fractions containing supposedly identified compounds in order to confirm the molecular structures proposed by the database at the end of the dereplication process.
Résultats Results
Le procédé de fermentation génère un extrait fermenté de graines de Longoza ayant une composition très différente des extraits de Longoza non fermentés, par exemple un extrait aqueux de Longoza non-fermenté extrait avec 100 % eau. The fermentation process generates a fermented Longoza seed extract having a very different composition from non-fermented Longoza extracts, for example an aqueous non-fermented Longoza extract extracted with 100% water.
En particulier, l’extrait fermenté de graines de Longoza comprend différents acides organiques, comme illustré dans le Tableau 1 ci-dessous. In particular, the fermented extract of Longoza seeds includes different organic acids, as shown in Table 1 below.
Tableau 1 : Acides organiques présentes dans l’extrait fermenté de graines d’Aframomum angustifolium ou Longoza par rapport à un extrait aqueux de Longoza (non-fermenté) (en mg par rapport au g d’extrait sec) [Table 1 ]
nd : non détecté Table 1: Organic acids present in the fermented extract of Aframomum angustifolium or Longoza seeds compared to an aqueous extract of Longoza (non-fermented) (in mg compared to g of dry extract) [Table 1] nd: not detected
Exemple 3 : Effet de l’extrait fermenté de graines de Longoza sur l’expression des protéines de la peau Example 3: Effect of Fermented Longoza Seed Extract on Skin Protein Expression
L’effet de l’extrait fermenté de graines de Longoza sur l’expression de plusieurs protéines marqueurs de la fonction barrière cutanée, la cohésion de l’épiderme, l’élasticité de la peau et l’éclat a été évalué. The effect of fermented Longoza seed extract on the expression of several protein markers of skin barrier function, epidermal cohesion, skin elasticity and radiance was evaluated.
Matériel et méthodes Material and methods
Culture et traitement des KHN Cultivation and treatment of KHN
Des Kératinocytes Humains Normaux (KHN) sont ensemencés dans des flasks TPP150 dans du milieu Epilife complémenté. Les KHN sont trypsinés à pré-confluence (0,05% Trypsin-EDTÀ, GIBCO-Invitrogen), et neutralisés avec un milieu contenant du sérum. Ensuite, ils sont ensemencés dans des plaques 96 puits imagerie (p-plate 96 well, ibiTreat, Ibidi) à raison de 10 000 cellules par puits. Normal Human Keratinocytes (KHN) are seeded in TPP150 flasks in supplemented Epilife medium. The KHNs are trypsinized at pre-confluence (0.05% Trypsin-EDTA, GIBCO-Invitrogen), and neutralized with a medium containing serum. They are then seeded in 96-well imaging plates (96-well p-plate, ibiTreat, Ibidi) at a rate of 10,000 cells per well.
À confluence, les KHN sont traités avec l’extrait fermenté de graines de Longoza L2 ou L3 dans du milieu Epilife complet contenant 500 M de CaC (0,2 mL/puits). L’extrait L2 et/ou L3 a été testé à une concentration de 0,02 % et/ou 0,1 % v/v. Le traitement est réalisé pendant 3 ou 5 jours avec un remplacement du milieu de culture au bout de 48h. Pour les conditions témoin (non traité), le milieu est remplacé par du milieu neuf contenant 500pM de CaC . At confluence, the KHNs are treated with the fermented extract of Longoza L2 or L3 seeds in complete Epilife medium containing 500 M of CaC (0.2 mL/well). The L2 and/or L3 extract was tested at a concentration of 0.02% and/or 0.1% v/v. The treatment is carried out for 3 or 5 days with replacement of the culture medium after 48 hours. For the control conditions (untreated), the medium is replaced with new medium containing 500 μM of CaC.
Marquage des cellules Cell labeling
À l’issu des traitements, les cellules sont fixées à la formaline (Formalin Solution 10% Neutral Buffered, Sigma) pendant 10 minutes puis perméabilisées avec une solution de PBS-Triton 0,1 % (Triton X-100, Sigma). Elles sont ensuite saturées avec du PBS/BSÀ 1 % (PBS : solution saline tamponnée au phosphate BSÀ : albumine de sérum bovin), pendant 30 minutes et à température ambiante. La solution de PBS/BSÀ 1 % est ensuite remplacée par
une solution d’anticorps primaire correspondant à chaque protéine marquée (voir tableau 2) diluée dans du PBS/BSÀ 1%. Les plaques sont incubées une nuit à 4°C. At the end of the treatments, the cells are fixed with formalin (Formalin Solution 10% Neutral Buffered, Sigma) for 10 minutes then permeabilized with a solution of PBS-Triton 0.1% (Triton X-100, Sigma). They are then saturated with PBS/BSA 1% (PBS: phosphate-buffered saline solution BSA: bovine serum albumin), for 30 minutes and at room temperature. The 1% PBS/BS solution is then replaced with a solution of primary antibody corresponding to each labeled protein (see Table 2) diluted in PBS/1% BS. The plates are incubated overnight at 4°C.
Après rinçage par du PBS, les cellules sont recouvertes d’une solution d’anticorps secondaire (anticorps de cheve anti-lapin ou anti-souris, Alexa Fluor 568 d’Invitrogen) selon l’anticorps primaire à cibler au 1 /300ème et de DAPI au 1 /500ème (4’,6’-diamidino-2-phenylindole, dihydrochloride, Invitrogen Molecular Probes) dilués dans le PBS/BSA 1%. Les plaques sont incubées une heure à l’obscurité et à température ambiante. After rinsing with PBS, the cells are covered with a solution of secondary antibody (anti-rabbit or anti-mouse goat antibody, Alexa Fluor 568 from Invitrogen) depending on the primary antibody to be targeted at 1/ 300th and of DAPI at 1/500th (4′,6′- diamidino -2-phenylindole, dihydrochloride, Invitrogen Molecular Probes) diluted in PBS/BSA 1%. The plates are incubated for one hour in the dark and at room temperature.
Après rinçage par du PBS suivi par l’eau distillée, du PBS est déposé dans chaque puits à raison de 1 mL. Les plaques sont conservées à 4° C et à l’obscurité jusqu’à l’acquisition des images. After rinsing with PBS followed by distilled water, PBS is deposited in each well at the rate of 1 mL. Plates are stored at 4°C in the dark until image acquisition.
Tableau 2 : Récapitulatif des anticorps primaires utilisés [Table 2]
Table 2: Summary of primary antibodies used [Table 2]
Acquisition d’image par HCS et analyse Image acquisition by HCS and analysis
Les plaques sont scannées à l’ « ArrayScan XTi » de Thermo Cellomics. The plates are scanned with the “ArrayScan XTi” from Thermo Cellomics.
Conditions d’acquisition : Vesting conditions:
Détection : Detection:
DAPI : filtre XF53_386_23
Alexa Fluor 568 : filtre XF53_572_15 DAPI: filter XF53_386_23 Alexa Fluor 568: filter XF53_572_15
Résolution : 1104 x 1104 Resolution: 1104 x 1104
Objectif : 10x dry Objective: 10x dry
Nombre d’images : 25 par puits Number of images: 25 per well
Les images ont été analysées à l’aide du logiciel d'analyse d'image « Spot detector », bio-qui détecte le marquage rouge de la protéine ciblée, correspondant à l’expression de celle-ci. La surface de la zone de mesure est délimitée comme étant la totalité de la surface de l’image. Le nombre de cellules est déterminé par le comptage des noyaux par détection du marquage bleu. The images were analyzed using “Spot detector” image analysis software, which detects the red labeling of the targeted protein, corresponding to its expression. The surface of the measurement area is delimited as being the entire surface of the image. The number of cells is determined by counting the nuclei by detecting the blue label.
Selon les marqueurs et leur expression cellulaire, les résultats peuvent être exprimés par :Depending on the markers and their cellular expression, the results can be expressed by:
- Intensité du marquage détecté (seuillage) / nombre de cellules - Intensity of the labeling detected (threshold) / number of cells
- Intensité du marquage dans le champ total / nombre de cellules - Marking intensity in the total field / number of cells
La significativité des différences des rapports observées entre les témoins et les traités est mesurée par le test de Student (* p<0,05, ** p<0,01 ). The significance of the differences in the ratios observed between the controls and the treated is measured by the Student test (*p<0.05, **p<0.01).
Résultats Results
3.1. Expression de la loricrine 3.1. Expression of loricrin
La loricrine est une protéine structurelle exprimée au niveau de l’enveloppe cornée qui contribue à la fonction barrière de la peau. Loricrin is a structural protein expressed at the level of the horny envelope which contributes to the barrier function of the skin.
L’extrait fermenté de graines de Longoza augmente l’expression de la loricrine de façon significative avec un effet dose observé lorsque la concentration d’extrait est augmentée (+41 % pour l’extrait L2 à une concentration de 0,02 % et +57 % pour l’extrait L2 à une concentration de 0,1 %, p<0,01 , voir la Figure 1 ). The fermented extract of Longoza seeds significantly increases the expression of loricrin with a dose effect observed when the concentration of extract is increased (+41% for the L2 extract at a concentration of 0.02% and + 57% for the L2 extract at a concentration of 0.1%, p<0.01, see Figure 1).
3.2. Expression de la filaggrine 3.2. Filaggrin expression
Comme la loricrine, la filaggrine est une protéine impliquée dans la fonction barrière de la peau. Like loricrin, filaggrin is a protein involved in the barrier function of the skin.
L’extrait fermenté de graines de Longoza augmente l’expression de la filaggrine de façon significative avec un effet dose observé lorsque la concentration d’extrait est augmentée (+7,5 % pour l’extrait L3 à une concentration de 0,1 % et +17,8 % pour l’extrait L2 à une concentration de 0,1 %, p<0,01 , voir la Figure 2).
3.3. Expression de l’élafine The fermented extract of Longoza seeds increases the expression of filaggrin significantly with a dose effect observed when the concentration of extract is increased (+7.5% for the L3 extract at a concentration of 0.1% and +17.8% for the L2 extract at a concentration of 0.1%, p<0.01, see Figure 2). 3.3. Expression of elafin
L’élafine est une protéine impliquée dans la fonction barrière cutanée. Elle a également un effet inhibiteur sur l’élastase, empêchant ainsi la dégradation des fibres élastiques. Elafin is a protein involved in the skin barrier function. It also has an inhibitory effect on elastase, thus preventing the degradation of elastic fibers.
L’extrait fermenté de graines de Longoza augmente l’expression de l’élafine de façon significative avec un effet dose observé lorsque la concentration d’extrait est augmentée. En effet, l’expression est augmentée de +38,9 % pour l’extrait L3 à une concentration de 0,02 % et de +52,6 % pour l’extrait L3 à une concentration de 0,1 % (p<0,05, voir la Figure 3). De façon similaire, l’expression est augmentée de +37 % pour l’extrait L2 à une concentration de 0,02 % et de +45,8 % pour l’extrait L2 à une concentration de 0,1 % (p<0,05, voir la Figure 3). The fermented extract of Longoza seeds significantly increases the expression of elafin with a dose effect observed when the concentration of extract is increased. Indeed, the expression is increased by +38.9% for the L3 extract at a concentration of 0.02% and by +52.6% for the L3 extract at a concentration of 0.1% (p< 0.05, see Figure 3). Similarly, the expression is increased by +37% for the L2 extract at a concentration of 0.02% and by +45.8% for the L2 extract at a concentration of 0.1% (p<0 .05, see Figure 3).
3.4. Expression de la kallicréine 5 3.4. Expression of kallikrein 5
La kallicréine 5 est une protéine impliquée dans l’homéostasie et la desquamation de la peau. Elle contribue également à l’éclat de la peau. Kallikrein 5 is a protein involved in skin homeostasis and desquamation. It also contributes to the radiance of the skin.
L’extrait fermenté de graines de Longoza augmente l’expression de la kallicréine 5 de façon significative (+15,2 % pour l’extrait L3 à une concentration de 0,02 % et +11 % pour l’extrait L3 à une concentration de 0,1 %, p<0,05, voir la Figure 4). The fermented extract of Longoza seeds increases the expression of kallikrein 5 significantly (+15.2% for the L3 extract at a concentration of 0.02% and +11% for the L3 extract at a concentration 0.1%, p<0.05, see Figure 4).
3.5. Expression de la desmogléine 1 3.5. Expression of desmoglein 1
La desmogléine 1 est une protéine essentielle à l’intégrité de l’épiderme, assurant la structure de celle-ci par sa fonction adhésive au sein des jonctions intracellulaires (desmosomes). Elle favorise également la différenciation des kératinocytes. Desmoglein 1 is a protein essential to the integrity of the epidermis, providing its structure through its adhesive function within intracellular junctions (desmosomes). It also promotes the differentiation of keratinocytes.
L’extrait fermenté de graines de Longoza augmente l’expression de la desmogléine 1 de façon significative (+30,4 % pour l’extrait L3 à une concentration de 0,02 % et +17 % pour l’extrait L2 à une concentration de 0,02 %, p<0,01 , voir la Figure 5). The fermented extract of Longoza seeds increases the expression of desmoglein 1 significantly (+30.4% for the L3 extract at a concentration of 0.02% and +17% for the L2 extract at a concentration 0.02%, p<0.01, see Figure 5).
3.6. Expression de la transglutaminase 3.6. Expression of transglutaminase
La transglutaminase est une enzyme est impliquée dans la réticulation de protéines structurelles pour former l’enveloppe cornée dans l’épiderme. Elle contribue ainsi à la fonction barrière de la peau. Transglutaminase is an enzyme involved in the cross-linking of structural proteins to form the horny envelope in the epidermis. It thus contributes to the barrier function of the skin.
L’extrait fermenté de graines de Longoza augmente l’expression de la transglutaminase de façon significative (+73,8 % pour l’extrait L2 à une concentration de 0,1 % et +97,6 % pour l’extrait L3 à une concentration de 0,1 %, p<0,01 , voir la Figure 6). The fermented extract of Longoza seeds increases the expression of transglutaminase significantly (+73.8% for the L2 extract at a concentration of 0.1% and +97.6% for the L3 extract at a concentration of concentration of 0.1%, p<0.01, see Figure 6).
3.7. Expression de la ZO-1
ZO-1 est une protéine intercellulaire impliquée dans la formation des jonctions serrées entre les cellules de la peau. Elle contribue ainsi à la fonction barrière et l’intégrité de la peau.3.7. Expression of ZO-1 ZO-1 is an intercellular protein involved in the formation of tight junctions between skin cells. It thus contributes to the barrier function and the integrity of the skin.
L’extrait fermenté de graines de Longoza augmente l’expression de la ZO-1 de façon significative (+25,8 % pour l’extrait L2 à une concentration de 0,1 % et +49,7 % pour l’extrait L3 à une concentration de 0,1 %, p<0,01 , voir la Figure 7). The fermented extract of Longoza seeds increases the expression of ZO-1 significantly (+25.8% for the L2 extract at a concentration of 0.1% and +49.7% for the L3 extract at 0.1% concentration, p<0.01, see Figure 7).
Conclusions Findings
Deux extraits de graines de Longoza fermentés, L2 et L3, ont été testés sur l’expression de marqueurs de la différenciation épidermique sur un modèle de kératinocytes humains normaux en culture notamment afin de déterminer leur activité sur la barrière cutanée. Two fermented Longoza seed extracts, L2 and L3, were tested on the expression of epidermal differentiation markers on a model of normal human keratinocytes in culture, in particular to determine their activity on the skin barrier.
Les extraits ont des effets positifs sur l’expression de marqueurs de la barrière cutanée tels que l’élafine impliquée dans la constitution de l’enveloppe cornée ou la desmogléine 1 constitutive des jonctions desmosomales. Par ailleurs, l’extrait L3 augmente l’expression de la kallicréine 5, impliqué dans l’homéostasie et la desquamation de la peau. The extracts have positive effects on the expression of skin barrier markers such as elafin involved in the constitution of the horny envelope or desmoglein 1 constitutive of desmosomal junctions. In addition, the L3 extract increases the expression of kallikrein 5, involved in homeostasis and desquamation of the skin.
Exemple 4 : Effet de l’extrait fermenté de graines de Longoza sur un modèle de peauExample 4: Effect of Fermented Longoza Seed Extract on a Skin Model
L’effet de l’extrait fermenté de graines de Longoza selon la présente invention sur l’élasticité, la fermeté, et la densité cellulaire de la peau a été évalué dans un modèle de peau dépiété en cellules souches. The effect of the fermented Longoza seed extract according to the present invention on the elasticity, firmness, and cell density of the skin was evaluated in a stem cell-depleted skin model.
Matériel et méthodes Material and methods
Établissement du modèle de peau reconstruite bio-imprimée déplétée en cellules souches épidermiques (CSE) Establishment of the bio-printed reconstructed skin model depleted in epidermal stem cells (ESC)
Bio-impression des dermes papillaires et réticulaires par extrusion Bio-printing of papillary and reticular dermis by extrusion
Les poudres entrant dans la composition de la bio-encre ont été dissoutes dans du DMEM sans calcium et placées sous agitation à 37° C sur la nuit. The powders entering into the composition of the bio-ink were dissolved in calcium-free DMEM and placed under stirring at 37° C. overnight.
Le lendemain, des fibroblastes papillaires/réticulaires, jeunes ou âgés, à confluence, ont été trypsinés et comptés. La quantité nécessaire de cellules a été prélevée, à raison de 250,000 fibroblastes par millilitre d’encre préparée, puis centrifugée. Le culot cellulaire a été directement remis en suspension dans le volume de bio-encre adéquat. Puis le mélange bio-encre/cellules a été transféré dans une seringue stérile montée sur une canule de 20 gauges.
Les objets imprimés ont été modélisés avec le logiciel Slic3r (GNU Àffero General Public License) et Repetier (Hot-World GmbH & Co. KG). Les couches de derme papillaire et derme réticulaire ont été imprimées en 2 temps, l’une sur l’autre. Des dermes « âgés » et de dermes « jeunes » ont été imprimées. The following day, confluent young or old papillary/reticular fibroblasts were trypsinized and counted. The necessary quantity of cells was removed, at the rate of 250,000 fibroblasts per milliliter of ink prepared, then centrifuged. The cell pellet was directly resuspended in the appropriate volume of bio-ink. Then the bio-ink/cell mixture was transferred into a sterile syringe mounted on a 20 gauge cannula. The printed objects were modeled with the software Slic3r (GNU Àffero General Public License) and Repetier (Hot-World GmbH & Co. KG). The papillary dermis and reticular dermis layers were printed in 2 stages, one on top of the other. “Aged” dermis and “young” dermis were printed.
Dans un premier temps, des cubes de dimensions 1 ,5 cm x 1 ,5 cm x 0,2 cm ont été imprimés avec les encres contenant les fibroblastes papillaires. La hauteur de ces objets correspondait à deux couches superposées. Suite à cette première impression, des cubes de dimensions 1 ,5 cm x 1 ,5 cm x 0,1 cm (équivalent à 1 couche) ont été imprimés au-dessus des premiers cubes de 2 couches. Ces construits ont ensuite été placés pendant 1 heure dans une solution de calcium et thrombine permettant la polymérisation et consolidation de la bio-encre. Après trois rinçages dans un tampon salin, les dermes équivalents ont été mis en culture dans du MCF (préparation interne de LabSkin Creations, milieu adapté à la culture des fibroblastes) et placés à l’incubateur (37° C, 5 % CO2) puis cultivés 7 jours avant l’ensemencement des kératinocytes triés à leur surface. Le milieu de culture a été renouvelé tous les 2 jours. Initially, cubes of dimensions 1.5 cm×1.5 cm×0.2 cm were printed with the inks containing the papillary fibroblasts. The height of these objects corresponded to two superimposed layers. Following this first printing, cubes of dimensions 1.5 cm×1.5 cm×0.1 cm (equivalent to 1 layer) were printed above the first cubes of 2 layers. These constructs were then placed for 1 hour in a solution of calcium and thrombin allowing the polymerization and consolidation of the bio-ink. After three rinses in a saline buffer, the dermal equivalents were cultured in MCF (internal preparation from LabSkin Creations, medium adapted to the culture of fibroblasts) and placed in an incubator (37° C., 5% CO2) then cultured 7 days before the seeding of the sorted keratinocytes on their surface. The culture medium was renewed every 2 days.
Tri magnétique selon le marqueur CD71 sur kératinocytes primaires en cultureMagnetic sorting according to the CD71 marker on primary keratinocytes in culture
Tout d’abord, des kératinocytes primaires adultes ont été décongelés à passage 1 dans des flasques de culture dans du milieu de culture MCK (préparation interne de LabSkin Creations, milieu adapté à la culture des kératinocytes). Après une semaine d’amplification, à confluence, les cellules ont été trypsinées puis comptées. L’ensemble de ces cellules a été trié avec le kit de billes magnétiques CD71 130-046-201 (Miltenyi) selon les instructions du fournisseur. First, primary adult keratinocytes were thawed at passage 1 in culture flasks in MCK culture medium (LabSkin Creations internal preparation, medium suitable for keratinocyte culture). After one week of amplification, at confluence, the cells were trypsinized and then counted. All of these cells were sorted with the CD71 magnetic bead kit 130-046-201 (Miltenyi) according to the supplier's instructions.
Brièvement, les kératinocytes ont été incubés 15 minutes à +4°C avec les billes magnétiques selon un ratio cellules/volume de billes défini. Ce mélange a ensuite été centrifugé, puis le surnageant a été éliminé pour se débarrasser des billes magnétiques non liées aux cellules d’intérêt. Le culot de kératinocytes a été remis en suspension dans du milieu de culture, et a été passé sur les colonnes magnétiques installées sur l’aimant prévu à cet effet. La fraction négative qui contient les cellules n’exprimant pas le marqueur de surface CD71 , correspondant à une population enrichie en cellules souches épidermiques non retenue dans la colonne, a été récoltée en premier dans un tube stérile. Briefly, the keratinocytes were incubated for 15 minutes at +4° C. with the magnetic beads according to a defined cell/bead volume ratio. This mixture was then centrifuged and then the supernatant was discarded to get rid of the magnetic beads not bound to the cells of interest. The pellet of keratinocytes was resuspended in culture medium, and was passed over the magnetic columns installed on the magnet provided for this purpose. The negative fraction which contains cells not expressing the CD71 surface marker, corresponding to a population enriched in epidermal stem cells not retained in the column, was harvested first in a sterile tube.
Par la suite, la colonne a été décrochée du support magnétique et rincée, permettant de récolter les cellules exprimant le marqueur de surface CD71 (fraction déplétée en cellules souches) qui étaient liées aux billes magnétiques. Les fractions enrichies et déplétées en cellules ont été comptées afin de calculer le ratio CD71 -/CD71 +.
En parallèle de cette extraction, des kératinocytes de prépuce préalablement mis en culture ont également été trypsinés et comptés pour être ensemencés le même jour sur les dermes. Ceux-ci constituent le « contrôle jeune ». Subsequently, the column was unhooked from the magnetic support and rinsed, making it possible to harvest the cells expressing the surface marker CD71 (fraction depleted in stem cells) which were bound to the magnetic beads. The fractions enriched and depleted in cells were counted in order to calculate the CD71 −/CD71 + ratio. In parallel with this extraction, foreskin keratinocytes previously cultured were also trypsinized and counted to be seeded the same day on the dermis. These constitute the “young control”.
Ensemencement des kératinocytes CD71 + sur les dermes bio-imprimés Seeding of CD71+ keratinocytes on bio-printed dermis
Une fois le tri magnétique effectué et les différentes fractions comptées, le milieu de culture des dermes bio-imprimés « jeunes » et « âgés » a été éliminé. Once the magnetic sorting was carried out and the different fractions counted, the culture medium of the “young” and “old” bioprinted dermis was eliminated.
L’équivalent de 500 000 kératinocytes CD71 + a été déposé à la surface des dermes âgés. Il en a été fait de même avec une suspension de kératinocytes de prépuce, ensemencée à la surface des dermes « contrôle jeune », servant de référence. The equivalent of 500,000 CD71+ keratinocytes have been deposited on the surface of aged dermis. The same was done with a suspension of foreskin keratinocytes, seeded on the surface of the “young control” dermis, serving as a reference.
Après 30 minutes d’adhésion à +37° C, du milieu a été utilisé pour submerger les ensembles dermo-épidermiques. After 30 minutes of adhesion at +37°C, medium was used to submerge the dermo-epidermal assemblies.
Les ensembles dermo-épidermiques ont été cultivés durant 3 jours dans du milieu MCK permettant la prolifération des kératinocytes. Ils ont ensuite été élevés à l’interface air/liquide afin d’initier la différenciation des épidermes. Cette ultime étape de culture a duré une semaine afin d’obtenir des épidermes pluristratifiés mais pas complètement matures. The dermo-epidermal assemblies were cultured for 3 days in MCK medium allowing the proliferation of keratinocytes. They were then raised at the air/liquid interface in order to initiate epidermal differentiation. This final culturing step lasted a week in order to obtain pluristratified but not completely mature epidermis.
L’extrait L2 ou L3 a été ajouté au milieu de culture. Le milieu a ensuite été filtré afin d’éviter tout risque de contamination. Les extraits ont été appliqués aux cultures cellulaires quotidiennement pendant les 5 derniers jours de culture (cultures arrêtées au jour 35).The L2 or L3 extract was added to the culture medium. The medium was then filtered to avoid any risk of contamination. The extracts were applied to the cell cultures daily for the last 5 days of culture (cultures stopped at day 35).
Des échantillons ont été fixés en solution de formol tamponné 4 % (Alphapath, France) puis inclus en paraffine. Samples were fixed in 4% buffered formalin solution (Alphapath, France) then embedded in paraffin.
Coloration histologique à l’hématoxyline phloxine safran Histological staining with hematoxylin phloxine saffron
Des coupes paraffine de 5pM ont été préparées. Après déparaffinage et réhydratation, les échantillons ont été colorés à l’Hématoxyline-Phloxine-Safran (HPS). 5 µM paraffin sections were prepared. After deparaffinization and rehydration, the samples were stained with Hematoxylin-Phloxine-Saffron (HPS).
Immunofluorescence sur coupes inclues en paraffine Immunofluorescence on sections embedded in paraffin
Un marquage anti-intégrine alpha 6 a été réalisé sur des coupes de 5 et 20 micromètres d’épaisseur. Après un démasquage à la chaleur, une étape de saturation en PBS/BSA 4% a permis de bloquer les sites antigéniques aspécifiques. Les cellules ont ensuite été incubées sur la nuit avec un anticorps primaire spécifique de l’antigène intégrine alpha 6 au 1 /10 000ème (anticorps monoclonal de lapin, Abeam) puis avec un anticorps secondaire Alexa- Fluor 568 anti-lapin dilué au 1 /1000ème (Thermo Fisher Scientific, MA, USA) et le colorant
nucléaire Hoechst (Thermo Fisher Scientific). Un témoin négatif sans anticorps primaire a été réalisé en parallèle. Alpha 6 anti-integrin labeling was performed on sections 5 and 20 micrometers thick. After heat unmasking, a saturation step in PBS/BSA 4% made it possible to block the aspecific antigenic sites. The cells were then incubated overnight with a primary antibody specific for the alpha 6 integrin antigen at 1/ 10,000th (rabbit monoclonal antibody, Abeam) then with an anti-rabbit Alexa-Fluor 568 secondary antibody diluted to 1 /1000 th (Thermo Fisher Scientific, MA, USA) and the dye nuclear Hoechst (Thermo Fisher Scientific). A negative control without primary antibody was carried out in parallel.
Acquisition des images Image acquisition
Les colorations histologiques et marquages immunohistologiques ont été observés avec le système microscope optique Axio Observer D1 / caméra haute résolution Axiocam (Zeiss, Le Pecq, France). Les images ont été acquises à l’aide du logiciel ZEN pro 2012 et sauvegardées en format « tif » (haute résolution). Histological staining and immunohistological staining were observed with the Axio Observer D1 optical microscope system/Axiocam high-resolution camera (Zeiss, Le Pecq, France). Images were acquired using ZEN pro 2012 software and saved in “tif” (high resolution) format.
Acquisition des données microscopie à force atomique (AFM) Data Acquisition Atomic Force Microscopy (AFM)
L’AFM utilisé est un bioscope Resolve (Bruker) sur lequel a été monté un microscope à épifluorescence (Leica DMi8) permettant la réalisation d’études corrélatives (image AFM/Fluorescence). The AFM used is a Resolve bioscope (Bruker) on which was mounted an epifluorescence microscope (Leica DMi8) allowing the realization of correlative studies (AFM/Fluorescence image).
Le mode PeakForce® QNM/ Fast-Force volume a été utilisé. La sonde AFM qui a été choisie présente une constante de raideur théorique de 0.4N/m et de rayon de courbure <10nm. Avant chaque utilisation la sensibilité de déflexion de la sonde a été mesurée sur du Saphir et sa constante de raideur a également été calibrée par la méthode du bruit thermique. Le levier de l’AFM a été positionné sur la Jonction Dermo-Epidermique (JDE) visible grâce à l’immunomarquage anti-intégrine alpha 6 réalisé sur coupes congelées. PeakForce® QNM/Fast-Force volume mode was used. The AFM probe that was chosen has a theoretical stiffness constant of 0.4N/m and a radius of curvature <10nm. Before each use, the deflection sensitivity of the probe was measured on Saphir and its stiffness constant was also calibrated by the thermal noise method. The lever of the AFM was positioned on the Dermo-Epidermal Junction (DEJ) visible thanks to the anti-integrin alpha 6 immunostaining carried out on frozen sections.
Une analyse AFM complète a consisté en l’acquisition d’un force volume de la zone d’intérêt (JDE) en conditions aqueuses (PBS 1X). A complete AFM analysis consisted of the acquisition of a force volume of the zone of interest (JDE) in aqueous conditions (PBS 1X).
Les paramètres utilisés pour les acquisitions ont été : The parameters used for the acquisitions were:
- Matrice de force/volume : 20pm x 20pm - 64px2 - Force/volume matrix: 20pm x 20pm - 64px2
- Courbes de force : Force = 20nN - Ramp size = 10 pM - Force curves: Force = 20nN - Ramp size = 10 pM
Pour l’imagerie AFM du derme, le mode Force Volume a également été utilisé. Des forces volumes ont été acquises sur différentes zones des coupes avec les mêmes paramètres que précédemment. For AFM imaging of the dermis, the Force Volume mode was also used. Volume forces were acquired on different areas of the cuts with the same parameters as before.
Analyses quantitatives : extraction du module élastique (Ea) Quantitative analyses: extraction of the elastic modulus (Ea)
Les quantifications du Ea à partir des courbes de forces brutes ont été réalisées à l’aide du logiciel de traitement BioMeca Analysis (BioMeca). Ea quantifications from raw force curves were performed using BioMeca Analysis processing software (BioMeca).
Les courbes d’approche brutes obtenues pour chaque section ont été traitées pour en extraire une quantification précise du Ea (rigidité) de la JDE. Ici, le modèle théorique de Sneddon a été appliqué à une indentation comprise entre 0 et 1 M. À l’aide des différentes matrices de force, les variations d’élasticité de la jonction dermo-épidermique pour chaque
section ont été extraites. Analyses statistiques : Contrôle jeune versus Agé dépiété CSE non traité : t-test, $$$ p<0,001 ; Agé dépiété CSE non traité versus Agé dépiété CSE traité avec L3 à 0,05% ou 0,1% : t-test, *** p<0,001. The raw approach curves obtained for each section were processed to extract an accurate quantification of the Ea (stiffness) of the JDE. Here, Sneddon's theoretical model was applied to an indentation between 0 and 1 M. Using the different force matrices, the elasticity variations of the dermal-epidermal junction for each section were extracted. Statistical analyses: Young control versus elderly depleted CSE untreated: t-test, $$$ p<0.001; Depleted elderly CSE untreated versus Depleted elderly CSE treated with L3 at 0.05% or 0.1%: t-test, *** p<0.001.
Résultats Results
4.1. Analyse histologique 4.1. Histological analysis
Le traitement avec l’extrait fermenté de graines de Longoza (L2 ou L3, à une concentration de 0,05 ou 0,1 %) a permis l’obtention de dermes cellularisés présentant une couche de fibroblastes néosynthétisés plus importante que celle observée dans les échantillons non traités. Les épidermes ont également une structure améliorée : ils sont apparus plus épais, avec une organisation basale très nette et une JDE structurée. La différenciation de ce compartiment n’a pas été perturbée par l’administration de l’extrait - bien au contraire, une couche cornée est présente dans toutes les conditions. Enfin, l’extrait fermenté de graines de Longoza L3 semblent présenter un effet dose avec une couche de fibroblastes sous la jonction dermo-épidermique plus épaisse avec la dose à 0,1 %. Treatment with the fermented extract of Longoza seeds (L2 or L3, at a concentration of 0.05 or 0.1%) made it possible to obtain cellularized dermis presenting a layer of newly synthesized fibroblasts greater than that observed in the untreated samples. The epidermis also have an improved structure: they appeared thicker, with a very clear basal organization and a structured JDE. The differentiation of this compartment was not disturbed by the administration of the extract - quite the contrary, a stratum corneum is present in all conditions. Finally, the fermented extract of Longoza L3 seeds seems to present a dose effect with a thicker layer of fibroblasts under the dermo-epidermal junction with the 0.1% dose.
4.2. Immunomarquage 4.2. Immunolabelling
Une analyse du profil d’expression de l’intégrine apha-6 a permis une étude plus précise de la partie basale de l’épiderme contenant les populations de cellules souches épidermiques. Les peaux reconstruites déplétées en CSE et traitées avec l’extrait fermenté de graines de Longoza L3, à une concentration de 0,05 ou 0,1 %, ont vu leur expression de l’intégrine alpha 6 largement augmentée, révélant des populations de cellules souches épidermiques, solidement ancrées à la jonction dermo-épidermiques, plus importantes. Les taux d’expression de ce marqueur atteint des niveaux comparables voire supérieurs à celui observé dans les échantillons de peaux reconstruites « jeune ». An analysis of the expression profile of the integrin apha-6 allowed a more precise study of the basal part of the epidermis containing the populations of epidermal stem cells. The reconstructed skins depleted in CSE and treated with the fermented extract of Longoza L3 seeds, at a concentration of 0.05 or 0.1%, saw their expression of integrin alpha 6 largely increased, revealing cell populations epidermal strains, firmly anchored at the dermo-epidermal junction, more important. The expression levels of this marker reach levels comparable or even higher than that observed in samples of “young” reconstructed skin.
4.3. AFM 4.3. AFM
Une analyse du module élastique des JDE obtenues dans chacune des conditions de traitement par AFM ont permis de confirmer les résultats cités ci-dessus (voir figure 9). Les traitements avec l’extrait L3 à 0,05 ou 0,1 % ont conduit à une augmentation de la population de cellules souches épidermiques et ainsi à une augmentation du module élastique (L3 à 0,05 % : +48 %, p<0,001 ; L3 à 0,1 % : +96 %, p<0,001 ), mesuré au niveau de la JDE, signifiant que ces jonctions sont plus rigides. L’extrait fermenté de graines de Longoza a par ailleurs
montré un effet dose, le module élastique augmentant avec la concentration d’actif appliquée dans le milieu de culture. An analysis of the elastic modulus of the JDEs obtained under each of the AFM treatment conditions made it possible to confirm the results cited above (see FIG. 9). Treatments with the L3 extract at 0.05 or 0.1% led to an increase in the population of epidermal stem cells and thus to an increase in the elastic modulus (L3 at 0.05%: +48%, p<0.001; L3 at 0.1%: +96%, p<0.001), measured at the JDE, meaning that these junctions are stiffer. The fermented extract of Longoza seeds has also showed a dose effect, the elastic modulus increasing with the concentration of active ingredient applied in the culture medium.
Aussi, l’extrait fermenté de graines de Longoza L3, en induisant une augmentation du compartiment prolifératif au niveau basal de l’épiderme, permet l’obtention d’une JDE plus rigide et plus fortement ancrée ainsi que des épidermes plus épais et prolifératifs qui présentaient toutefois une différenciation satisfaisante. Also, the fermented extract of Longoza L3 seeds, by inducing an increase in the proliferative compartment at the basal level of the epidermis, makes it possible to obtain a stiffer and more strongly anchored JDE as well as thicker and proliferative epidermis which however, showed satisfactory differentiation.
Exemple 5 : Formulations cosmétiques Example 5: Cosmetic formulations
L’extrait fermenté de graines de Longoza tel que préparé à l’exemple 1 est formulé dans les compositions illustratives et non limitatives suivantes, préparées selon les méthodes classiques de formulation en cosmétique. The fermented extract of Longoza seeds as prepared in Example 1 is formulated in the following illustrative and non-limiting compositions, prepared according to conventional cosmetic formulation methods.
5.1. Composition sous la forme d’une lotion 5.1. Composition in the form of a lotion
[Table 3]
[Table 3]
* préparé selon l’exemple 1 * prepared according to example 1
Appliquée sur la peau, en particulier sur le visage, cette composition apporte une action anti-âge avec des effets bénéfiques sur la fermeté et/ou l’élasticité de la peau. Applied to the skin, in particular to the face, this composition provides an anti-aging action with beneficial effects on the firmness and/or elasticity of the skin.
5.2. Composition sous la forme d’un sérum 5.2. Composition in the form of a serum
[Table 4]
[Table 4]
‘préparé selon l’exemple 1 ‘prepared according to example 1
Le sérum est appliqué sur l’ensemble du visage et en particulier sur les zones présentant des signes de vieillissement. Le sérum comprenant l’extrait fermenté de graines de Longoza selon l’invention favorise le renouvellement épidermique, pour une peau élastique, plus ferme et un teint plus homogène.
The serum is applied all over the face and especially on areas showing signs of aging. The serum comprising the fermented extract of Longoza seeds according to the invention promotes epidermal renewal, for elastic, firmer skin and a more even complexion.
Claims
1 . Extrait fermenté de graines d’Aframomum angustifolium ou de Longoza comprenant :1 . Fermented extract of Aframomum angustifolium or Longoza seeds comprising:
- une teneur en acide quinique comprise entre 0,05 et 2 % ; et - a quinic acid content of between 0.05 and 2%; and
- une teneur en acide acétique comprise entre 5 et 15 %, en poids par rapport au poids d’extrait sec de l’extrait fermenté. - an acetic acid content of between 5 and 15%, by weight relative to the dry extract weight of the fermented extract.
2. Extrait fermenté de graines d’Aframomum angustifolium ou de Longoza selon la revendication 1 , caractérisé en ce qu’il est sous forme liquide et qu’il comprend au moins un conservateur, de préférence sélectionné parmi le butylène glycol, la glycérine, le propylène glycol, le benzoate de sodium benzoate et le sorbate de potassium. 2. Fermented extract of Aframomum angustifolium or Longoza seeds according to claim 1, characterized in that it is in liquid form and that it comprises at least one preservative, preferably selected from butylene glycol, glycerin, propylene glycol, sodium benzoate benzoate and potassium sorbate.
3. Procédé de fermentation de graines d’Aframomum angustifolium ou de Longoza comprenant les étapes suivantes : a) l’incubation d’un consortium de micro-organismes dans une solution comprenant un glucide à une température comprise entre 17 à 38°C pendant 1 à 10 jours afin d’obtenir une culture de micro-organismes, ledit consortium comprenant au moins une bactérie lactique appartenant au genre Lactobacillus ou Pediococcus, au moins une levure appartenant au genre Saccharomyces, Schyzosaccharomyces ou Torulaspora, et au moins une bactérie acétique appartenant au genre Acetobacter, Gluconobacter ou Komagataeibacter b) le broyage de graines d’Aframomum angustifolium ou de Longoza afin d’obtenir une poudre composée de particules ayant une taille moyenne comprise entre 100 pm et 1 mm ; c) l’ajout de ladite poudre dans un milieu fermentaire comprenant la culture de microorganismes afin d’obtenir un mélange de fermentation, ledit milieu fermentaire comprenant un glucide choisi parmi le saccharose, le glucose, le fructose, la mélasse ou un mélange d’un ou plusieurs de ceux-ci, d) l’incubation du mélange de fermentation à une température comprise entre 25 et 35° C pendant 7 à 13 jours ; e) la filtration du mélange de fermentation afin d’obtenir un extrait fermenté de graines d’Aframomum angustifolium ou Longoza. 3. Process for the fermentation of Aframomum angustifolium or Longoza seeds comprising the following steps: a) the incubation of a consortium of microorganisms in a solution comprising a carbohydrate at a temperature of between 17 and 38°C for 1 to 10 days in order to obtain a culture of microorganisms, said consortium comprising at least one lactic bacterium belonging to the genus Lactobacillus or Pediococcus, at least one yeast belonging to the genus Saccharomyces, Schyzosaccharomyces or Torulaspora, and at least one acetic bacterium belonging to the genus Acetobacter, Gluconobacter or Komagataeibacter b) the grinding of seeds of Aframomum angustifolium or of Longoza in order to obtain a powder composed of particles having an average size of between 100 μm and 1 mm; c) adding said powder to a fermentation medium comprising the culture of microorganisms in order to obtain a fermentation mixture, said fermentation medium comprising a carbohydrate chosen from sucrose, glucose, fructose, molasses or a mixture of one or more of these, d) incubating the fermentation mixture at a temperature between 25 and 35°C for 7 to 13 days; e) filtration of the fermentation mixture to obtain a fermented extract of Aframomum angustifolium or Longoza seeds.
4. Procédé selon la revendication 3, dans laquelle environ 60 g de poudre ou moins est ajouté par litre de milieu fermentaire à l’étape a), plus préférentiellement environ 50 g de poudre ou moins, encore plus préférentiellement environ 12 g/L ou 50 g/L.
35 4. Process according to claim 3, in which approximately 60 g of powder or less is added per liter of fermentation medium in step a), more preferentially approximately 50 g of powder or less, even more preferentially approximately 12 g/L or 50g/L. 35
5. Procédé selon la revendication 3 ou A, dans laquelle le milieu fermentaire comprend en outre un extrait aqueux de feuilles de thé. 5. Method according to claim 3 or A, in which the fermentation medium further comprises an aqueous extract of tea leaves.
6. Extrait fermenté de graines d’Aframomum angustifolium ou de Longoza obtenu par le procédé selon l’une quelconque des revendication 3 à 5. 6. Fermented extract of Aframomum angustifolium or Longoza seeds obtained by the process according to any one of claims 3 to 5.
7. Composition cosmétique comprenant, dans un milieu physiologiquement acceptable, un extrait fermenté de graines d’Aframomum an ustifolium ou de Longoza selon la revendication 1 , 2 ou 6. 7. Cosmetic composition comprising, in a physiologically acceptable medium, a fermented extract of Aframomum an ustifolium or Longoza seeds according to claim 1, 2 or 6.
8. Composition cosmétique selon la revendication 7, caractérisée en que l’extrait fermenté de graines d’Aframomum an ustifolium ou de Longoza est présent en une teneur allant de 0,0000012 % à 0,0825 %, de préférence de 0,000006 % à 0,033 %, plus préférentiellement de 0,000012 % à 0,0165 % en poids de matière active (matière sèche d’extrait fermenté de graines d’Aframomum an ustifolium ou de Longoza) par rapport au poids total de ladite composition. 8. Cosmetic composition according to claim 7, characterized in that the fermented extract of Aframomum an ustifolium or Longoza seeds is present in a content ranging from 0.0000012% to 0.0825%, preferably from 0.000006% to 0.033%, more preferably from 0.000012% to 0.0165% by weight of active ingredient (dry matter of fermented extract of Aframomum an ustifolium or Longoza seeds) relative to the total weight of said composition.
9. Composition cosmétique selon l’une quelconque des revendications 7 à 8, caractérisée en ce qu’elle comprend en outre au moins un adjuvant cosmétique choisi dans le groupe constitué par des agents antioxydants, des agents émollients, des agents hydratants, des agents anti-âge, des parfums, et leurs mélanges. 9. Cosmetic composition according to any one of claims 7 to 8, characterized in that it further comprises at least one cosmetic adjuvant chosen from the group consisting of antioxidant agents, emollient agents, moisturizing agents, anti-aging agents. -age, perfumes, and mixtures thereof.
10. Composition cosmétique selon l’une quelconque des revendications 7 à 9, caractérisée en ce qu’elle est sous la forme d’une crème, émulsion huile-dans-eau, ou eau-dans-huile ou émulsion multiple, solution, suspension, gel, lait, lotion, ou sérum. 10. Cosmetic composition according to any one of claims 7 to 9, characterized in that it is in the form of a cream, oil-in-water emulsion, or water-in-oil or multiple emulsion, solution, suspension , gel, milk, lotion, or serum.
11. Procédé cosmétique de soin et/ou maquillage des matières kératiniques, en particulier de la peau et/ou des lèvres, comprenant l’application sur lesdites matières kératiniques, d’au moins une couche d’une composition cosmétique telle que définie dans l’une quelconque des revendications 7 à 10. 11. Cosmetic process for caring for and/or making up keratin materials, in particular the skin and/or the lips, comprising the application to said keratin materials of at least one layer of a cosmetic composition as defined in any of claims 7 to 10.
12. Procédé cosmétique selon la revendication 11 , caractérisé en ce qu’il est destiné à favoriser et/ou stimuler le renouvellement épidermique, la desquamation de la peau, la vitalité des cellules cutanées, et/ou la cohésion des cellules cutanées, et/ou prévenir et/ou
diminuer les signes du vieillissement cutané, notamment la perte de fermeté, la perte d’élasticité, la perte de densité, l’apparition de rides et/ou ridules, la sécheresse de la peau, l’altération de la fonction barrière de la peau, l’altération de la souplesse de la peau et/ou l’altération de l’homogénéité ou de l’éclat du teint. 12. Cosmetic process according to claim 11, characterized in that it is intended to promote and / or stimulate epidermal renewal, desquamation of the skin, the vitality of skin cells, and / or the cohesion of skin cells, and / or warn and/or reduce the signs of skin aging, in particular loss of firmness, loss of elasticity, loss of density, appearance of wrinkles and/or fine lines, dryness of the skin, alteration of the barrier function of the skin , the alteration of the suppleness of the skin and/or the alteration of the homogeneity or the radiance of the complexion.
13. Utilisation cosmétique d’un extrait fermenté de graines d’Aframomum angustifolium ou de Longoza tel que défini selon l’une des revendications 1 , 2 ou 6 comme actif pour favoriser et/ou stimuler le renouvellement épidermique, la desquamation de la peau, la vitalité des cellules cutanées, et/ou la cohésion des cellules cutanées, et/ou prévenir et/ou diminuer les signes du vieillissement cutané, notamment la perte de fermeté, la perte d’élasticité, la perte de densité, l’apparition de rides et/ou ridules, la sécheresse de la peau, l’altération de la fonction barrière de la peau, l’altération de la souplesse de la peau et/ou l’altération de l’homogénéité ou de l’éclat du teint.
13. Cosmetic use of a fermented extract of Aframomum angustifolium or Longoza seeds as defined according to one of claims 1, 2 or 6 as an active ingredient for promoting and/or stimulating epidermal renewal, desquamation of the skin, the vitality of skin cells, and/or the cohesion of skin cells, and/or preventing and/or reducing the signs of skin aging, in particular loss of firmness, loss of elasticity, loss of density, the appearance of wrinkles and/or fine lines, dryness of the skin, alteration of the barrier function of the skin, alteration of the suppleness of the skin and/or alteration of the homogeneity or radiance of the complexion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2014275A FR3118422B1 (en) | 2020-12-30 | 2020-12-30 | Longoza seed fermented extract |
PCT/FR2021/052388 WO2022144513A1 (en) | 2020-12-30 | 2021-12-17 | Fermented extract of longoza seeds |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4271208A1 true EP4271208A1 (en) | 2023-11-08 |
Family
ID=75339873
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21854927.7A Pending EP4271208A1 (en) | 2020-12-30 | 2021-12-17 | Fermented extract of longoza seeds |
Country Status (7)
Country | Link |
---|---|
US (1) | US20240099961A1 (en) |
EP (1) | EP4271208A1 (en) |
JP (1) | JP2024501552A (en) |
KR (1) | KR20230128047A (en) |
CN (1) | CN116916763A (en) |
FR (1) | FR3118422B1 (en) |
WO (1) | WO2022144513A1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2891458B1 (en) * | 2005-10-04 | 2008-01-18 | Lvmh Rech | COSMETIC COMPOSITIONS INCLUDING ANTI-AGING ACTIVITY COMPRISING AN EXTRACT FROM THE AFRAMOMUM ANGUSTIFOLIUM OR LONGOZA PLANT. |
FR2934491B1 (en) * | 2008-08-01 | 2010-09-17 | Lvmh Rech | COSMETIC COMPOSITION CONTAINING AN ASSOCIATION OF LIPOCHROMAN-6 AND A LOGOZA EXTRACT AND USE THEREOF |
FR3075638B1 (en) * | 2017-12-22 | 2020-03-13 | Lvmh Recherche | COSMETIC COMPOSITIONS IN PARTICULAR WITH ANTI-AGING ACTIVITY COMPRISING A GREEN EXTRACT FROM THE PLANT AFRAMOMUM ANGUSTIFOLIUM OR LONGOZA |
-
2020
- 2020-12-30 FR FR2014275A patent/FR3118422B1/en active Active
-
2021
- 2021-12-17 CN CN202180094794.0A patent/CN116916763A/en active Pending
- 2021-12-17 JP JP2023540094A patent/JP2024501552A/en active Pending
- 2021-12-17 EP EP21854927.7A patent/EP4271208A1/en active Pending
- 2021-12-17 US US18/268,679 patent/US20240099961A1/en active Pending
- 2021-12-17 WO PCT/FR2021/052388 patent/WO2022144513A1/en active Application Filing
- 2021-12-17 KR KR1020237025447A patent/KR20230128047A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2024501552A (en) | 2024-01-12 |
KR20230128047A (en) | 2023-09-01 |
FR3118422B1 (en) | 2023-01-20 |
FR3118422A1 (en) | 2022-07-01 |
WO2022144513A1 (en) | 2022-07-07 |
CN116916763A (en) | 2023-10-20 |
US20240099961A1 (en) | 2024-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1132463B1 (en) | Cosmetic composition comprising an antagonist of the neuropeptide Y receptor | |
EP2953611B1 (en) | Use of a composition comprising avocado perseose in the protection of epidermal stem cells | |
WO2001045648A2 (en) | Use of a vaccinium-type extract as an anti-glycation agent | |
EP2986347B1 (en) | Cosmetic applications of lactobacillus pentosus | |
EP3370833B1 (en) | Synergistic extract of palmaria palmata | |
FR2801504A1 (en) | Extract of Ajuga turkestanica is a keratinocyte differentiation agent and dermal hydrating agent, for cosmetic treatment to prevent sign of aging | |
EP0681831A2 (en) | Use of extracts of filamentous bacteria as cosmetic agents against skin aging | |
WO2008152268A2 (en) | Cosmetic composition containing an adenium obesum extract, use thereof and method for cosmetic care including the use thereof | |
WO2020126653A1 (en) | Rosewood extract | |
EP1743628A1 (en) | Cosmetic composition containing red algae extract comprising a combination of floridoside and isethionic acid. | |
EP1054660B1 (en) | Cosmetic composition containing a compound with activity stimulating interleukin-6 | |
WO1996025143A1 (en) | Cosmetic or pharmaceutical, particularly dermatological, composition containing a bertholletia extract | |
EP2958547B1 (en) | Cosmetic use of queuine | |
EP4271208A1 (en) | Fermented extract of longoza seeds | |
FR3104416A1 (en) | Rose bud extracts | |
EP3620212B1 (en) | Fermented violet extract, method for obtaining such an extract and use in cosmetics | |
WO2021116616A1 (en) | Cosmetic composition comprising extracts of pomegranate and peony | |
FR3116731A1 (en) | Fermented extract of Ikaria honey | |
WO2022112725A2 (en) | Fermented extract of ushant honey | |
FR2749168A1 (en) | USE OF LABANAN FURANOID DITERPENOIDS FOR THE PREPARATION OF COSMETIC OR PHARMACEUTICAL COMPOSITIONS AND SKIN CELL CULTURE MEDIA | |
EP4262743A1 (en) | Dendrobium fimbriatum extract and no-rinse cosmetic composition comprising same | |
WO2021123699A1 (en) | Cosmetic composition comprising a yeast extract debaryomyces nepalensis | |
EP4043005A1 (en) | Cosmetic composition comprising a yeast hydrolysate | |
WO2021111096A1 (en) | Cosmetic composition comprising extracts of kigelia and nasturtium | |
TW202313087A (en) | Prunus salicinaferment, manufacturing method thereof, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230622 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |